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SURVEILLANCE, PREVENTION AND SURGICAL TREATMENTS FOR
HEPATOCELLULAR CARCINOMA
Kerui Xu, Ph.D.
University of Nebraska, 2018

Supervisor: Shinobu Watanabe-Galloway, Ph.D.
Liver cancer is the second-leading cause of cancer death, representing roughly
9.1% of all cancer mortality. Of all primary cancers of the liver, hepatocellular carcinoma
(HCC) accounts for roughly 85%. HCC has been increasing in the U.S. and other countries.
In particular, HCC places a huge burden on the Chinese population, as China alone
consists of approximately 50% of the total HCC cases and deaths. In China, chronic
hepatitis B virus (HBV) infection is the leading cause for developing HCC. The two
challenges in prevention and control of HCC experienced in China are low rates of HCC
screening among the high-risk populations and poor adherence to HBV antiviral therapy.
As of this date, there is a dearth of research in surveying high-risk populations with chronic
viral hepatitis to evaluate the compliance, knowledge level, and self-identified barriers to
recommended HCC screening and antiviral medication treatment. In addition to its high
incidence and mortality rates in China, HCC is also a major disease burden in the U.S.,
where HCC is currently the fastest growing cause of cancer-related death. As HCC often
leads to poor survival, it is critical to initiate early treatment. Currently, there are no
established guidelines to define the optimal time interval from diagnosis to surgery.
Knowledge regarding to the impact of HCC treatment delays is solely based on results
produced from medical records-based studies conducted in single centers, and findings
have been inconsistent. The main objectives of this dissertation are to 1) investigate the
practice, knowledge and barriers for HCC screening in high-risk Chinese patients, 2)
assess the medication adherence and perceived barriers to oral antiviral therapy for
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chronic HBV treatment, and 3) utilize the Commission on Cancer’s National Cancer
Database to examine the association between surgical treatment delays and long-term
survival in HCC patients.
In the results of the first objective, we observed that among 352 high-risk patients
for HCC, 50.0% had routine HCC screening, 23.3% had irregular screening and 26.7%
had incomplete or no screening. The most frequent barriers reported for not receiving
screening were not aware that screening for HCC exists (41.5%), no symptoms or
discomfort (38.3%), and lack of recommendation from physicians (31.9%). The results of
the second objective showed that among 369 patients with chronic HBV, only 16.5% were
measured with high adherence while 51.2% had low adherence utilizing the Morisky
Medication Adherence Scale. The most common reasons for skipping HBV antiviral
medications were that medication(s) are expensive (48.7%), forgetfulness (45.1%), have
experienced or worry about potential side effects (19.8%). The results of the third objective
showed that using a wait time cutoff at 60 days from the date of HCC diagnosis to definitive
surgery, delayed patients demonstrated significantly better 5-year survival for local tumor
destruction (29.1% vs. 27.6%) and hepatic resection (44.1% vs. 41.0%). Risk-adjusted
model indicated that delayed patients had a 7% decreased risk of death.
The findings of these studies may assist healthcare providers and researchers to
develop more effective educational programs to improve patients’ awareness, knowledge
and perceptions about HCC prevention and control, actively identify the high-risk patients
for undergoing HCC screening, and provide better disease management and timely
treatment for patients with chronic viral hepatitis to decrease the likelihood of developing
HCC. For treating HCC patients, using a national hospital-based cancer registry, our study
added new evidence that delay in HCC surgery was associated with a decreased risk of
mortality. The finding calls for the need to conduct prospective studies to assess the case
prioritization approach and its level of impact in HCC surgical care.
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CHAPTER 1
INTRODUCTION

Specific aims
According to the Global Burden of Disease 2015 study, there were an estimated
854,000 new cases and 810,000 deaths due to liver cancer in 2015 [1]. Liver cancer is the
sixth most common malignancy worldwide, but it is the second-leading cause of cancer
death, representing roughly 9.1% of all cancer mortality [2]. Globally, liver cancer is the
fifth most common cancer in males and seventh in females [2], and hepatocellular
carcinoma (HCC) accounts for roughly 85% of primary cancer of the liver [3].
Of all countries worldwide, HCC places a huge burden on the Chinese population,
as China alone has about 50% of the total HCC cases and deaths [4]. In China, chronic
hepatitis B virus (HBV) infection is the leading cause for developing HCC, and one-third
of the world’s total populations who are chronically infected with HBV are residing in China
[5]. The two challenges in prevention and control of HCC experienced in China are low
rates of HCC screening among the high-risk populations and poor adherence to HBV
antiviral therapy, which have been likely attributed by a lack of health awareness,
inadequate knowledge about liver disease progression, and high costs associated with
managing hepatitis infection [6-10]. As of date, there is a dearth of research in surveying
high-risk populations with chronic viral hepatitis to evaluate the compliance, knowledge
level, and self-identified barriers to compliance with guidelines recommended HCC
screening and antiviral medication treatment.
In addition to its high incidence and mortality rates in China, HCC has also become
a major disease burden in the U.S [11], where HCC currently is the fastest growing cause
of cancer-related death in the U.S. [11]. As HCC often leads to poor survival with an
estimated 5-year survival rate of just 17.7% [12], it is critical to initiate early treatment once
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diagnosis has been confirmed. Currently, there are no established guidelines to define
surgical delay in HCC-directed surgery or the optimal time interval from diagnosis to
surgery. Knowledge regarding the impact of HCC treatment delays is solely based on
results produced from medical records-based studies conducted in single centers, and
findings have been largely inconsistent [13-19].
In this dissertation, the long-term goals are to develop more effective strategies to
prevent or slow down disease progression to liver cancer among high-risk populations
who are infected with chronic viral hepatitis, and to provide evidence-based
recommendations for improved disease management and timely treatment in patients with
liver cancer. To achieve these goals, we seek to better understand the preventive
measures and treatments that are available for liver cancer, which include cancer
screening and antiviral treatment for the high-risk populations, and curative cancerdirected surgery for patients with liver cancer. There are three specific aims pursued as
part of this dissertation:

Aim 1: To investigate HCC screening practice among high-risk Chinese patients, to
identify the sociodemographic and clinical factors related to HCC screening practice, to
examine the association of sociodemographic and clinical factors with HCC screening
knowledge level, and to identify the perceived barriers to HCC screening.

Aim 2: To determine rates of medication adherence to NUC antiviral therapy among
Chinese patients with chronic HBV using the Morisky Medication Adherence scale, to
identify the self-perceived barriers to NUC adherence, and to investigate the impact of
sociodemographic and clinical factors, treatment-related factors, and perceptions of
disease on NUC adherence.
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Aim 3: To identify the demographic and clinical factors associated with delay in HCC
surgical treatment, and to evaluate the association of surgical delay and long-term survival
in HCC patients, using records queried from the Commission on Cancer’s National Cancer
Database.

The findings of these studies will contribute to the increase of knowledge on the adherence
and self-identified barriers to disease management and HCC prevention among patients
chronically infected with viral hepatitis. We will also acquire a better understanding about
the relationship of surgical treatment delay or prolonged surgical wait-time and cancer
survival in HCC patients. These results are expected to have a significant and positive
impact on promoting cancer prevention in patients with chronic viral hepatitis and timely
treatment for patients with HCC. The study findings could ultimately serve to reduce the
likelihood of developing HCC among the high-risk patients, and increase the chances of
survival among those who have already developed HCC.

Hepatocellular Carcinoma Overview
Epidemiology of HCC
Liver cancer is the sixth most common malignancy worldwide, but it is the secondleading cause of cancer death, representing roughly 9.1% of all cancer mortality. Globally,
liver cancer is the fifth most common cancer in males and seventh in female [2], and HCC
accounts for the majority (~85%) of primary cancer of the liver [3]. According to 2015 global
estimates, there were an estimated 854,000 new cases and 810,000 deaths due to liver
cancer [1]. Liver cancer has a higher prevalence in developing countries as most cases
(~83%) are diagnosed in less developed nations [20]. It is the third most common cancer
in developing countries among men, following lung and stomach cancer [21]. Liver cancer,
in particular, places a huge burden on the Chinese population. China alone accounts for
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approximately 50% of the total number of liver cancer cases and deaths globally [4].
Moreover, liver cancer is identified as the second leading cause of cancer death among
males and third among females in China [4]. In terms of economic burden, using the
Chinese hospital information database that consisted of 350 million inpatient records, in
year of 2015, total health care expense for liver cancer treatment was 10.2 billion RMB.
This was only ranked behind treatment for cancers of the lung (24.3 billion), colon and
rectum (20.8 billion), stomach (15.7 billion), breast (11.5 billion) and cervix (11.5 billion)
[22]. In addition to causing major health issues in China, in the United States, liver cancer
is one of the fastest growing causes of cancer-related death [11]. According to 2017
estimates, there were 40,710 newly diagnosed cases and 28,920 associated deaths of
liver cancer in the U.S. [23].

Risk factors of HCC
The major risk factors for developing HCC are infection with HBV or HCV, chronic
alcohol consumption, aflatoxin exposure, and non-alcoholic fatty liver disease potentially
associated with diabetes and obesity [3]. Nearly 50% of all cases of HCC in the world are
associated with HBV infection, while 25% of HCC cases are associated with HCV infection
[24]. Genetic risk factors include hereditary hemochromatosis, primary biliary cirrhosis,
autoimmune hepatitis, alpha 1-antitrypsin deficiency syndrome, and Wilson’s disease [25].
Obesity and diabetes mellitus are also known to be highly correlated with increased risk
for HCC [26]. In terms of environmental factors, chronic aflatoxin exposure is highly
associated with HCC as it can damage the DNA of hepatic cells [27]. Moreover, study has
found that due to synergistic effect, aflatoxin exposure increases the risk for HCC
progression when combined with HBV infection [28]. Aflatoxin is a mycotoxin that
contaminates stored foods, including corn, rice, soybeans and peanuts. Aflatoxin poses
as a more serious risk factor in people from Asian and African countries [28].
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Secondary Prevention for Hepatocellular Carcinoma
HCC screening
As liver cancer is a major disease burden, it is crucial to detect it in its early stage
so that timely treatments could be offered. Detection by routine screening is the best way
to improve survival and to achieve better prognosis. Commonly used screening tools
include serum alpha-fetoprotein (AFP), abdominal ultrasound, or a combination of both
tests [29]. Several guidelines on HCC surveillance have been published and updated
globally. A comparison of HCC screening guidelines developed and published by different
professional societies can be found in Appendix A. The combination of serum AFP and
ultrasound at 6-month intervals is the standard liver cancer screening method
recommended by the Asian Pacific Association for the Study of Liver (APASL) for
populations with high risk of developing liver cancer [30]. The high-risk populations for
developing HCC are patients with HBV infection, HCV infection, HBV and HCV coinfection,
cirrhosis, diabetes mellitus, and those with severe alcohol abuse or a family history of
HCC [31].
The clinical effectiveness of AFP has been demonstrated with randomized
controlled trials that involved more than 18,000 patients with a history of chronic hepatitis
or HBV infection, and the findings have indicated that biannual screening with AFP and
ultrasound reduced mortality by 37% [32]. In addition, several other studies have reported
screening to be cost-effective and effectual in reducing mortality in populations with HCV
infection and cirrhosis [33-35]. On the other hand, the liver cancer screening guidelines
developed by the American Association for the Study of Liver Diseases (AASLD)
recommend that patients with liver cirrhosis to undergo screening at 6-month intervals with
only ultrasound [36]. Studies have shown that AFP lacks efficacy as a surveillance test for
liver cancer, with an inadequate sensitivity and specificity at 66% and 82%, respectively
[37]. Comparatively, ultrasound was reported to have a sensitivity of between 65% to 80%,

19
and a specificity greater than 90% [38]. In addition, combined usage of ultrasound and
AFP can increase detection rates, but may increase false-positive rates and screening
costs. Employing only ultrasound has been indicated to have a 2.9% false-positive rate,
whereas the combination resulted in a 7.5% false-positive rate [39]. Although
disagreement exists for the application of AFP in liver cancer screening, both the APASL
and AASLD guidelines recommend screening at timely intervals of every 6 months for
high-risk populations.

Theoretical framework of barriers and facilitators for HCC screening
As shown in Figure 2, the framework that links the barriers and risk factors for HCC
screening is modified from the Health Belief Model [40]. The Health Belief Model was
developed in the early 1950s in order to understand the failure of populations to adopt
disease prevention measures or screening tests for early disease detection [40]. The
Health Belief Model emphasizes the theory that behaviors mainly depend upon the value
placed by an individual on a specific goal and the individual’s estimate of likelihood that
the action performed would achieve this goal [40]; this theory closely ties with the
dissertation study. When perceived barriers outweigh perceived benefits, the likelihood of
taking the recommended preventative health action decreases, leading to noncompliance
or a lack of adherence. In addition, an individual’s modifying factors can have an impact
on perceived susceptibility, perceived severity, perceived benefits, as well as perceived
threat. For instance, high-risk patients with cirrhosis are more likely to have higher level of
perceived severity and perceived threat compared to those without cirrhosis; therefore,
cirrhotic high-risk patients are more likely to undergo routine HCC screening due to a
greater level of perceived benefit.
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Modifying factors
Age, gender, region of
residency, education, income,
insurance, family history,
hepatitis infection history,
cirrhosis status, comorbidity,
liver cancer knowledge

Perceived susceptibility
Individuals with cirrhosis
or chronic hepatitis are at
increased risk for
developing HCC

Perceived threat
from HCC

Perceived severity
HCC yields poor prognosis

Cues to action
-Education provided from physicians
-Education provided from community
health promotion workers
-Reminders from healthcare
providers
-Undergoing screening due to
personal experiences
-Knowing someone with HCC
-Trust in HCC screening tests

Perceived benefits
Early diagnosis leads to
early treatment; HCC is
potentially curable in early
stage

Likelihood of behavior
change when
perceived benefits
outweigh perceived
barriers

Perceived barriers
-Not aware that screening exists
-No symptoms or discomfort
-Lack of physician recommendation
-Do not know the screening benefits
-Why bother screening if it is hard to
treat
-Financial difficulty
-Afraid of HCC detection
-Lack time
-Access difficulty
-Screening is not effective
-Not afraid to develop HCC

Figure 1. Theoretical framework of barriers and facilitators for HCC screening;
adapted from Health Belief Model, Janz & Becker, 1984 [40].

Knowledge and barriers to HCC screening
As HCC screening has been demonstrated to improve early cancer detection and
increase the chance for receiving curative treatments, which would ultimately result in
more optimal long-term survival [32], adherence to recommended bi-annual cancer
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screening is critical for HCC prevention. In order to develop and implement effective
interventions to improve HCC surveillance rates, there is a need to better understand and
characterize patient-level knowledge, attitudes and perceived barriers regarding HCC
screening. There is currently limited research conducted in the U.S., Taiwan, and China
that investigated the knowledge, awareness and perceptions on HCC surveillance [6, 8,
41]. Farvardin et al. surveyed 541 cirrhotic patients to determine patient reported factors
related to HCC surveillance in a racially diverse and socioeconomically disadvantaged
cohort of patients of a hospital in Dallas, Texas [41]. Patients were identified using a
validated set of ICD-9 codes for liver cirrhosis, and eligible participants were recruited to
complete a survey at the time of clinic appointment or by telephone. The survey consisted
of four sections, which included knowledge on HCC, potential barriers to HCC surveillance
completion, patient attitudes, and demographic information. The primary outcome was the
receipt of abdominal imaging for surveillance purposes within a 12-month period
preceding and 6-month period after administration of the survey. The findings indicated
that patients had an overall high level of HCC-related knowledge; however, interestingly,
48.6% considered that eating a healthy diet would preclude them from having to undergo
bi-annual HCC screening. Moreover, 34.0% indicated that HCC surveillance would not be
necessary with normal physical exams or without the presentation of clinical symptoms.
Of the 49.9% of patients who reported to have barriers for receiving HCC screening, the
most common reasons included “difficulty with the scheduling process” (30.5%), “costs of
surveillance testing” (25.3%), and “transportation difficulties” (17.3%). Furthermore,
patients who received HCC screening were 3.1 times more likely to acknowledge that
cirrhosis was a risk factor for HCC development [41].
A cross-sectional study carried out in an outpatient clinic of a medical center in
Taiwan utilized two structured questionnaires to measure the patient perceptions on HCC
prevention and knowledge regarding viral hepatitis and liver cancer [8]. A total of 400
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patients with chronic HBV and/or HCV were recruited, and the questionnaires were
designed based on concepts of the health belief model. The scale for perceptions on HCC
prevention comprised 34 questions concerning perceived susceptibility, perceived
severity, perceived benefits, perceived barriers, and cues to action. The scale for liver
cancer and hepatitis infection knowledge had 15 questions on topics that included liver
function, blood tests for hepatitis, hepatitis symptoms, modes of viral transmission, and
liver cancer screening. The researchers found that older patients, as well as those with
lower socioeconomic status, were more likely to have negative perceptions and had a
lower knowledge score. In the multivariable analysis, participants’ age and perceived
barriers were significantly associated with a willingness to undertake antiviral treatment
[8].
Moreover, it has been reported that there is a lack of awareness for HCC
prevention and surveillance among the general Chinese population. A survey study was
conducted among 1,300 participants within the inpatient unit of a tertiary hospital in
Southern China to assess the level of an inpatient population’s awareness and knowledge
about hepatitis infection and primary liver cancer [6]. The 51-item structured questionnaire
contained questions on sociodemographics, and knowledge regarding route of HBV
transmission, risk factors of HCC, symptoms and signs of HCC, preventive methods of
HCC, and management and treatments for HCC. The investigators reported that
participants’ level of education had the biggest impact on their total knowledge score, while
other factors including occupation, income, and any known history of cancer within families
had less impact [6].

Hepatocellular Carcinoma Prevention through Management of Chronic Hepatitis
due to HBV Infection
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As discussed previously, approximately 50% of all HCC cases in the world are
associated with HBV infection. It has been reported that the risk of developing HCC is 100
times greater among patients infected with HBV compared to those without the infection,
and the risk becomes even greater for patients with both HBV and cirrhosis [36]. In terms
of the mechanism of which HBV infection causes HCC, it is believed that HBV could be
directly oncogenic by incorporating itself into a host genetic material, where the HBV DNA
is integrated into chromosomes of the hepatocytes and serves as a precursor to HCC [42].
Another suggested mechanism of HBV-induced HCC is due to an indirect effect; this can
be achieved through the process of inflammation, regeneration, and cirrhosis due to HBV
infection [42]. According to World Health Organization (WHO), about 5% of healthy adults
infected with HBV will develop chronic infection [43]. Among chronically infected patients,
approximately 20-30% will eventually go on to develop cirrhosis or liver cancer [43]. A
study has reported that after being infected with HBV, it takes roughly 10 years to develop
chronic hepatitis; 20 years to develop cirrhosis and 30 years to develop HCC [44].
Although most HBV-infected patients who develop HCC also have cirrhosis (70-90%),
HBV can directly cause HCC without cirrhosis [45].
Although the incidence of HBV-associated HCC has decreased in the past few
decades, HBV is still responsible for nearly half of HCC cases globally [24]. To prevent
the development of HCC, it is of importance to implement effective preventive measures
to control and to manage HBV infection from further progression or deterioration. Such
preventive methods include widely promoting the HBV vaccine to immunize against the
virus [49, 50], undertaking recommended bi-annual HCC screening with ultrasound and
AFP, and undergoing nucleot(s)ide analogs antiviral therapy.
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Figure 2. Natural course of HBV disease progression; adapted from Sundaram & Kowdley,
2015 [46].

Epidemiology of HBV infection in China
In China, chronic HBV infection is the leading cause for developing HCC [47].
Globally, China is the nation with a high prevalence of HBV infection, as approximately
one-third of the total populations who are chronically infected with HBV are residing in
China [5]. According to a national sero-epidemiological survey conducted in 1992,
approximately 120 million people in China were infected with HBV [47]. Since chronic HBV
is a major health concern in China, the universal vaccination program for infants started
in 1992 has played an important role in changing the epidemiology of HBV infection in
China from highly to moderately endemic [9]. Yet, the timely dose of HBV vaccine
coverage is lower in the economically disadvantaged western and middle provinces than
the eastern provinces of China [48]. Moreover, immunization coverage is lower in rural
than in urban areas [49]. As HBV infection imposes considerable economic burden on the
infected patients and their families, and is responsible as a major national healthcare
spending [22], with a current 93 million HBV carriers and chronic HBV patients, HBV
infection remains a major issue in China [50].
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Nucleo(t)ide analogues therapy for chronic HBV
Among patients chronically infected with HBV, antiviral therapy plays an important
role in controlling the infection by slowing down disease progression to cirrhosis and liver
cancer [51]. There are two major groups of antiviral agents approved for the treatment of
chronic HBV. These are known as immunomodulatory agents, which include conventional
interferon alpha (IFN-α) and pegylated interferon alpha (PEG-IFNα), and five oral
nucleot(s)ide analogs (NUCs). The advantages associated with interferon-based therapy
consist of the lack of drug resistance and the finite duration of therapy. Nevertheless, a
large number of patients do not respond to this treatment and would still require long-term
management using NUCs [52]. The NUCs approved to be used as antiviral therapy include
lamivudine, telbivudine, entecavir, adefovir, and tenofovir [53]. NUCs target the HBV
polymerase, which is a multifunctional protein that is essential for viral replication. The
main function of NUCs is to eradicate HBV from the host. NUCs act by direct inhibition,
through acting as chain terminators by incorporating it into the viral DNA or through
competitive binding with the endogenous substrates [51]. While completely eradicating
HBV may be unlikely with antiviral therapy, NUCs serve to prevent the development of
cirrhosis, decompensated liver diseases and HCC [51]. Prolonged antiviral treatment
using NUCs has shown to improve liver histology by effectively reducing the grades of
inflammation and by reversal of liver cirrhosis [51].

HBV antiviral therapy in China
Five NUCs, conventional IFN-α, and two formulations of PEG-IFNα have been
approved for treating chronic HBV infection in China [54]. Based on guidelines established
by the Chinese Society of Hepatology and Chinese Society of Infectious Diseases, all
NUCs are recommended as first-choice treatments [55]. On the other hand, according to
the AASLD and several international guidelines, entecavir and tenofovir are
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recommended as the first-line of NUC therapy in the treatment of chronic HBV [56, 57].
Although randomized clinical trials have demonstrated that entecavir and tenofovir have
low incidence of drug resistance and a potent antiviral effect [54], due to the high costs of
these medications and inadequate medical insurance coverage, entecavir and tenofovir
are not affordable or reimbursable for many Chinese patients. Therefore, low-to-moderate
generic barrier drugs, including lamivudine, telbivudine, and adefovir dipivoxil are still
commonly used in China [9, 10]. Based on the average annual income of people from the
general Chinese population, entecavir and PEG-IFNα produced by foreign pharmaceutical
companies are very costly and are often only covered by a small proportion of health
insurance [54]. By using less costly drugs, the healthcare system reduces the cost for
treatment in the short term; however, medical expenses may increase in the long run as
some patients will develop suboptimal response and drug resistance [54].

Adherence and barriers to HBV antiviral therapy
Adherence to antiviral treatment is fundamental in the optimal clinical management
of patients with chronic HBV, and the majority of patients with chronic HBV require longterm and possibly lifelong treatment. As of this date, there are a limited number of studies
that utilized questionnaires to investigate the adherence to HBV antiviral treatment and
the factors associated with adherence in the U.S., Australia, and the Netherlands [58-60].
Chotiyaputta et al. recruited 111 patients with chronic HBV who were receiving NUC from
the University of Michigan Health Clinics, U.S. [58], and the participants were asked to
complete a survey every 3 months for up to one year. Adherence rate was defined as the
percentage of days patients took their HBV medications during the last 30 days, and
virological response was evaluated by monitoring serum HBV DNA every 3-6 months. The
medical records of patients were reviewed to retrieve information on medical history,
current and previous HBV treatments, and virological response. The investigators found
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that 69 patients (74.1%) reported a 100% adherence using the survey, and patients with
100% adherence were significantly older, more likely to be male, and had higher annual
household income compared to those without 100% adherence. The most common
reasons for missing HBV medication(s) during the past 30 days were attributed to
“forgetfulness” and “travelling away from home”. Chotiyaputta and colleagues also noted
that self-reporting of adherence to healthcare providers was inflated as 78 patients (83.9%)
reported 100% adherence to their healthcare providers. Additionally, patients with better
adherence to NUC treatment had a trend towards lower rate of virological breakthroughs
[58].
Giang and colleagues from Australia also assessed the adherence rates to NUC
therapy in patients with chronic HBV infection and evaluated the factors associated with
non-adherence [59]. This study was conducted in the liver clinics of a hospital in Australia,
and a total of 80 patients who were taking one or more NUCs were asked to complete a
32-item questionnaire. The patients were asked to rate their overall adherence to NUCs,
other prescription medications (if any), and scheduled appointments using visual analogue
scales that ranged from 1 to 10. A score of 1 indicated poor adherence or that they
frequently skipped taking NUCs/other prescription/appointments. On the other hand,
score of 10 meant that adherence was excellent and patients fulfilled these criteria 100%
of the time. The researchers reported that 49 patients (66%) had optimal adherence and
that 34 patients (43%) had omitted taking their NUCs sometime in the past. Of patients
who reported skipping medications, “forgetfulness” (56.3%), “ran out of medications”
(10.4%) and “a change in daily routine” (10.4%) were cited as the most common reasons
In addition, patients who reported low adherence to other prescription drugs were more
likely to skip NUCs, and patients who were cared by a language-discordant clinician were
more likely to have suboptimal adherence [59].
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A prospective study was conducted in the Netherlands to investigate adherence to
entecavir among 100 chronic HBV patients visiting the outpatient clinics of two academic
hospitals [60]. The participants were given medication dispenser that monitored entecavir
intake during the 16-week therapy period. HBV DNA was measured at the baseline and
after 16 weeks, and patients’ beliefs about medicine (assessed using the Beliefs About
Medicines Questionnaire (BMQ)), self-reported adherence (evaluated using the
Medication Adherence Report Scale (MARS)), as well as experiences regarding the
Sensemedic system (the Sensemedic medication dispenser monitors medication intake
real-time) were examined using a follow-up questionnaire. The primary endpoint was
adherence during 16 weeks, and adherence was calculated using the formula of (number
of treatment days – number of missed doses)/ number of treatment days. Adherence over
a 16-week period averaged 85%, with 70% of patients exhibiting good adherence (≥80%),
and 52% of patients measured to have at least 90% adherence. Patients with poor
adherence were significantly younger and had more indifferent attitudes towards entecavir.
Additionally, the investigators reported that they did not observe poor adherence to be
independently associated with virological response [60].

Tertiary Prevention for Hepatocellular Carcinoma
Surgical treatment options
Although there are a number of available prevention and control measures for HCC,
unfortunately, a large number of the high-risk patients with chronic viral hepatitis or
cirrhosis will eventually develop the disease and would therefore seek to receive curative
HCC treatments. According to reports published by the American Cancer Society, The
detrimental effect of liver cancer is indicated by its low survival rate, with 5-year relative
survival rates at 31%, 11% and 3%, respectively, for stages of localized, regional and
distant [61]. One of the main reasons for the low survival rate is that most patients are

29
diagnosed with liver cancer during the advanced stage, which cannot be curatively treated
and can only be provided with palliative treatment to relieve pain [62]. While certain
cancers may respond to adjuvant chemotherapy or radiation, neither chemotherapy nor
radiation for late-stage liver cancer reduces mortality rates. Nevertheless, there are
effective treatments during the early stage, which include surgically removing part of the
liver, local ablation of small lesions, and liver transplantation [29]. While the majority of
patients diagnosed with liver cancer in the early stage survive for more than 5 years, those
diagnosed in advanced stage usually survive for less than a year [62]. Moreover, survival
rates are often higher in patients who receive surgical treatments to remove the tumor,
regardless of stage, whereas untreated patients with advanced disease often survive for
less than 6 months [63].

Loco-regional therapies
Surgical resection and liver transplantation are the first line of treatment choices
with early stage tumors; however, resection can only be performed on a small proportion
of patients at the time of diagnosis (often due to compromised liver function) and there is
a shortage of liver donors for transplantation [64]. Therefore, locoregional therapies, which
are potentially curative treatments, are often offered to slow the advancement of disease
for patients waiting on transplantation [65]. Local ablative therapy is classified into two
groups: chemical ablation and thermal ablation [66]. Chemical ablation involves using
substances such as ethanol and acetic acid, while thermal ablation utilizes microwaves,
cryoablation, lasers, and radiofrequency [66]. Radiofrequency ablation (RFA) is the most
effective and a widely used local ablative method; it is also one of the best alternative
treatments for patients with early-stage HCC who are unable to receive resection or
transplantation. RFA is less invasive, less expensive, and has shown to have lower
complication rates and shorter length of stage than resection [67]. Percutaneous ethanol
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injection (PEI) can be used as an alternative therapy for small HCC tumors in patients who
are considered poor candidates for resection [68]. Furthermore, transarterial
chemoembolization (TACE) serves to manage multifocal HCC and tumors that are
unresectable to downstage lesions before transplantation takes place [36]; TACE is an
effective approach for intermediate-stage HCC.

Surgical resection
Hepatic resection is recommended to patients with preserved liver function and
with early stage tumor. Resection is considered ideal for patients with maintained hepatic
reserve, such as patients with single lesions and without evidence of vascular invasion
[69]. Since resection increases the risk of hepatic decompensation for patients with
cirrhosis, only those with Child-Pugh class A and well-compensated cirrhosis are
considered as candidates [66]. Compared to local-regional therapy, resection allows a
complete pathological analysis of the cancerous sample [68]. Although resection is
considered curative and that resected patients have five-year survival as high as 70%,
recurrence is still common [70]. The prognosis of resected patients is most heavily
influenced by tumor recurrence, and other factors such as tumor size, liver function, tumor
nodules, and portal pressure [71, 72].

Liver transplantation
Liver transplantation for HCC is considered the best treatment option for earlystage tumors, and it accounts for approximately 30% to 40% of all liver transplantations
[73]. Since transplantation deals with both the tumor and underlying liver disease, patients
who receive transplantation have the best chance of a cure compared to other treatments
[74]. Due to the worldwide liver shortage, not all HCC patients who are candidates for
transplantation are able to receive this procedure, and physicians are selecting patients
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with the most survival benefit after transplantation to efficiently use the scarce source of
liver grafts. Currently, the Milan criteria are the most widely used criteria (single tumor ≤5
cm or three tumors all ≤3 cm), and have shown to result in a 5-year survival rate of 75%
with tumor recurrence rate less than 15% [75-77]. In terms of organ allocation, the Model
for End-Stage Liver Disease (MELD), adopted by the United Network for Organ Sharing
(UNOS), is a popularly accepted allocation policy/system that serves to decrease waiting
time and drop-out rates. The MELD score accesses severity, and follows the principle of
allocating organs to patients who are at the highest risk of death during their wait time [78].
A downside of the MELD score is that it is not able to predict mortality among HCC patients;
thus, allocation system gives exemption points to HCC patients (which is allocated 6
months after listing) on the basis of tumor burden to equalize the risk of death [73].

Impact of surgical treatment delay on HCC outcomes
Due to the poor survival of HCC patients and that majority of the patients are not
eligible for curative treatment, it is necessary to initiate early therapy once a diagnosis has
been confirmed. Currently, there are no established guidelines for defining delay in HCCdirected surgery or the optimal time interval from diagnosis to surgery. Several studies
have investigated the clinical impact of HCC therapeutic delays or prolonged wait time on
patient outcomes, and results have been largely inconsistent [13-19]. A total of three
studies have investigated the survival impact of delayed locoregional therapies among
HCC patients in Taiwan [14, 15] and Canada [16], and all found that wait time was
associated with an increased risk of mortality [14-16]. A study in Taiwan conducted by Huo
and colleagues consisted of 144 Taiwanese patients with HCC who underwent
chemoembolization, percutaneous ethanol or acetic acid injection from 1998 to 2003 [14].
Delay was determined as >2 months between diagnosis to treatment, and survival rates
were compared between 48 patients with treatment delay versus 96 gender- and age-
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matched controls without delay. It was found that delayed HCC treatment was linked with
shortened overall survival [14]. Another study also conducted in Taiwan included 121 HCC
patients detected through a surveillance program who underwent RFA as the initial
treatment modality, and delayed surgery was defined as >5 weeks starting from diagnosis
[15]. The researchers found that a longer wait time was an independent predictor of poorer
survival [15]. Similarly, Brahmania et al. from Canada found that incremental 30-day wait
periods were associated with a 9% increased risk of residual tumor (HR: 1.09) and 23%
increased risk of death (HR: 1.23) [16]. In this study, the sample comprised 219 HCC
patients diagnosed between 2010 and 2013 in the University Health Network in Toronto.
All patients received curative intent RFA for HCC, and wait time was defined using 30-day
increments [16].
In addition to locoregional therapies, investigators have also evaluated the impact
of wait time on HCC outcomes in hepatic resection. One study conducted in Boston, U.S.
included 350 patients with various primary hepatobiliary tumors, and delay was considered
as >1 month from presentation until surgical referral [17]. The investigators observed that
delays adversely affected survival in resected patients. However, the results of this study
should be reviewed with caution as HCC only represented 24% of the primary liver tumors;
there is no comparison of tumor stage and analysis was not conducted for different types
of liver tumors [17]. A 2017 study published in Journal of Hepatology reported that delay
for ≥3 months from diagnosis to resection did not affect oncological recurrence and
survival outcomes [18]. This study was conducted prospectively from 2006 to 2016 in a
tertiary medical center in France to evaluate the impact of time to resection after diagnosis
on recurrence rate, recurrence-free survival, and intention-to-treat overall survival. The
study consisted of 100 patients who consecutively underwent curative-intent resection for
BCLC 0-A HCC, and multivariable analyses indicated that there was no statistically
significant difference for tumor recurrence rate (32% vs. 32%, P=1.0), recurrence-free
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survival (37% vs. 48%, P=0.42), and 5-year overall survival (82% vs. 80%, P=0.20) [18].
Thus far, this has been the only study that did not observe a statistically significant
relationship between wait time to HCC-directed surgery and long-term outcomes.
Additionally, a few other studies conducted in the U.S. have investigated the same
topic while combining HCC patients who received different types of treatment modalities
or cancer care, and analyzed them altogether [13, 19]. A retrospective cohort study was
conducted among 267 cirrhotic patients diagnosed with HCC in hospital in Dallas, Texas
between 2005 and 2012 [13]. Information on demographics, clinical history, laboratory
data, and dates of HCC diagnosis and treatment initiation were abstracted from medical
records.

HCC

treatments

included

liver

transplantation,

resection,

RFA,

chemoembolization, systemic chemotherapy, and supportive care. The researchers
reported that using a treatment delay cutoff at 3 months, therapeutic delay led to worse
prognosis [13]. On the other hand, a study conducted in the U.S. Department of Veterans
Affairs (VA) found that delay of 60 days from diagnosis to treatment was associated with
a decreased risk of death among VA patients treated with curative surgery, liver-directed
therapy, or chemotherapy for BCLC stage C HCC (HR: 0.50; 95% CI: 0.37–0.67) [19]. As
shown from the literature review, research on this topic has produced inconsistent findings,
and results of the majority of these studies were based on relatively small samples [1319].

Knowledge gaps
Gap 1. Knowledge, awareness and perceived barriers to hepatocellular carcinoma
screening in high-risk Chinese patients.
To prevent high-risk patients with liver cirrhosis, chronic HBV or chronic HCV from
developing HCC, it is of crucial significance to understand the current practice for HCC
screening in China. Routine screening is known as the best way to detect early-stage HCC
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and improve cancer survival and prognosis [29, 80]. Currently, there is limited literature
that examined the knowledge level, attitudes and self-reported barriers for undergoing
recommended HCC screening [8, 41]. Furthermore, although no population-based data
have been published about HCC screening rates in China, studies have suggested that
screening rate is low or less than optimal due to a lack of knowledge and awareness
among the general Chinese population and even among healthcare workers [6, 7]. In a
study that included Chinese public health workers in Hangzhou, Zhejiang province, 29%
were not aware that chronic HBV infection was a major risk factor for cirrhosis and liver
cancer, and 30% did not know about the importance of HBV vaccine [7]. Since screening
serves to detect HCC at an earlier stage, effective treatments could be offered to achieve
better chance of survival. As healthcare professionals recommend HCC screening for the
at-risk patients, it is essential to identify the self-identified barriers that hinder HCC
screening so that more effective approaches could be implemented to promote screening
for early cancer detection. Furthermore, it would also be of importance to identify the types
of patients who are less compliant to screening, so that preventive measures could
potentially target these populations. Therefore, to address these gaps, we propose to
investigate the practice, knowledge and perceived barriers to HCC screening in high-risk
Chinese patients (Aim 1).

Gap 2. Adherence rates and self-reported perceived barriers to NUC antiviral
therapy in Chinese patients with chronic HBV.
In managing patients with chronic HBV, antiviral therapy functions to slow down
and reverse disease progression, which serves to reduce the risk of developing cirrhosis,
liver failure and liver cancer. While a few studies have utilized questionnaires to investigate
the adherence to HBV antiviral treatment [58-60]; the studies were limited to relatively
small sample sizes. Research conducted by Chotiyaputta et al. consisted of 111 patients
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recruited from the University of Michigan Health Clinics [58], while Giang et al. and van
Vlerken et al. enrolled 80 and 100 participants [59, 60], respectively. In study carried out
in Australia, Giang and colleagues found that 74.1% of patients reported an adherence
rate of 100% [59], while 66% and 52% of patients from studies conducted in the U.S. and
the Netherlands were measured to have adherence rate of 90% [58, 60]. In addition to the
lack of sample size, there is a dearth of research focused to assess the self-perceived
barriers and facilitators for adherence to HBV antiviral therapy. Since China has a high
prevalence of chronic HBV infection, it is crucial to understand the obstacles for
undergoing HBV treatment using a validated instrument. Therefore, to have a more
comprehensive understanding about antiviral therapy utilization and obstacles that affect
HBV treatment, we propose to examine adherence rates and perceived barriers to NUC
antiviral therapy in Chinese patients with chronic HBV (Aim 2). In addition to China,
findings generated from this study may be utilized to develop strategic preventive
measures to improve antiviral therapy compliance in other regions of world with high
prevalence of HBV infections, including countries in East Asia, Southeast Asia and SubSahara Africa.

Gap 3. Survival impact of surgical treatment delay on long-term outcomes in HCC
patients.
Among chronically infected patients with viral hepatitis, approximately 20-30% will
eventually develop cirrhosis or HCC [47]. Once HCC diagnosis has been confirmed, there
are a few potentially curative surgery options for patients in early stage, including liver
transplantation, partial resection, and RFA. Due to the poor prognosis of HCC, it is
necessary to initiate early active therapy once the disease is diagnosed. Currently,
however, there are no established guidelines for defining surgical delay in HCC-directed
surgery. Several studies have investigated the clinical impact of HCC therapeutic delays
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or prolonged wait time on outcomes in patients who underwent locoregional therapies [1416], resection [17, 18], and with different treatments analyzed altogether [13, 19].
Nevertheless, most were restricted to single centers with limited sample sizes, ranging
from 100 to 742 cases.
Furthermore, the previous studies have produced inconsistent findings. The
majority of research found that prolonged wait time to surgery was linked with shortened
survival, including cases treated with loco-regional therapy and resection [13-17]. On the
other hand, a study conducted among VA patients found that surgical delay, defined as
60 days from diagnosis, was associated with a decreased risk of death [19]. Another study
that evaluated the survival impact of time to surgery in 100 patients who underwent
surgical resection for BCLC0-A HCC discovered that there was no association, and that a
delay of 3 months did not affect oncological outcome [18]. Due to these conflicting
observations, we propose to evaluate the association of surgical treatment delay and longterm prognosis in HCC patients (Aim 3). In contrast to the majority of existing studies that
utilized medical records, our retrospective analysis that is based on large comprehensive
clinical data provides a different perspective.

37
CHAPTER II
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Abstract
Background: hepatocellular carcinoma (HCC) is among the leading causes of
cancer deaths in China. Considering its poor prognosis when diagnosed late, Chinese
guidelines recommend biannual screening for HCC with abdominal ultrasound and serum
alpha-fetoprotein (AFP) test for high-risk populations.
Objectives: To investigate the practice, knowledge and self-perceived barriers for
HCC screening among high-risk hospital patients in China.
Methods: An interview-based questionnaire was conducted among Chinese
patients with liver cirrhosis, chronic hepatitis B and/or chronic hepatitis C infection from
outpatient clinics at two tertiary medical institutions in Shanghai and Wuhan, China.
Results: Among 352 participating patients, 50.0% had routine screening, 23.3%
had irregular screening and 26.7% had incomplete or no screening. Significant
determinants for screening included higher level of education, underlying liver cirrhosis, a
family history of HCC, and better knowledge concerning viral hepatitis, HCC, and HCC
screening guidelines. Moreover, factors associated with better knowledge were younger
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age, female gender, urban residency, education level of college or above, annual
household income of greater than 150K RMB, and longer duration of hepatitis infection.
The three most frequent barriers reported for not receiving screening were not aware that
screening for HCC exists (41.5%), no symptoms or discomfort (38.3%), and lack of
recommendation from physicians (31.9%).
Conclusions: Healthcare professionals and community leaders should actively
inform patients regarding the benefits of HCC screening through design of educational
programs. Such interventions are expected to increase knowledge about HCC and HCC
screening, as well as improve screening adherence and earlier diagnosis.

Introduction
HCC is a primary malignant neoplasm accounting for 85-90% of primary liver
cancer, which is the sixth most common cancer and the second-leading cause of cancer
death worldwide [4, 79]. Liver cancer places a huge burden on the Chinese population.
China alone accounts for approximately 50% of the total number of liver cancer cases and
deaths globally [4]. In addition, liver cancer is identified as the second leading cause of
cancer death among males and third among females in China [81]. In an effort to control
and to reduce the detrimental effects of liver cancer in China, guidelines recommend the
practice of screening for early cancer detection [32]. However, unlike in other East Asian
regions, such as Japan, Korea and Taiwan, there is no government-funded nationwide
HCC screening program for high-risk populations in China [82]. In China, the high-risk
populations for developing HCC are patients with HBV infection, HCV infection, HBV and
HCV coinfection, liver cirrhosis, diabetes mellitus, and those with severe alcohol abuse or
a family history of HCC [31].
The detrimental effect of liver cancer is characterized by its poor prognosis, with
5-year relative survival rate to be 10.1% in China [83]. Currently, there is no curative
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treatment for the intermediate or advanced stage of HCC, and most patients are
diagnosed during the advanced stage, which cannot be effectively treated [62]. While
certain cancers may respond to adjuvant chemotherapy or radiation, neither
chemotherapy nor radiation for late-stage HCC reduces mortality rates; nevertheless,
treatments are more effective for early stage of HCC, which include surgically removing
part of the liver, local ablation of small lesions and liver transplantation [29].
Routine screening is the best way to detect early-stage HCC and improve survival
and prognosis [29]. The screening guidelines for HCC developed by the American
Association for the Study of Liver Diseases (AASLD) recommend HCC screening every 6
months for high-risk individuals by abdominal ultrasound [36]. On the other hand,
screening guidelines published by the Peking University Medical Press and expert
consensus established by the Chinese Anti-Cancer Association Society of Liver Cancer,
Chinese Society of Clinical Oncology, and Chinese Society of Hepatology Liver Cancer
Study Group recommend biannual screening with a combination of serum Alphafetoprotein (AFP) and abdominal ultrasound at 6-month intervals for high-risk populations
[31, 84]. The clinical effectiveness of AFP has been demonstrated in 18,816 patients with
a history of chronic hepatitis or HBV infection, and findings indicated that biannual
screening with AFP and ultrasound reduced mortality by 37% [32]. In addition, a
combination of these two screening tests has been suggested as the most effective
strategy for detecting HCC at an early stage, and complementary usage improved
surveillance in patients with cirrhosis [85, 86].
While numerous studies have surveyed different populations to understand the
knowledge and barriers for cervical, breast and colorectal cancer screenings, it is difficult
to find similar studies conducted for HCC screening. Since healthcare professionals
recommend HCC screening for the at-risk patients [79, 80], it is crucial to identify the
barriers that hinder HCC screening so that more effective approaches can be implemented
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to promote screening. Furthermore, since liver cancer is a major health concern in China
and that China has a high number of HBV infected patients, it would be ideal to carry out
this research study among Chinese patients. The main objectives of this study were to i)
investigate HCC screening practice among high-risk Chinese patients, ii) identify the
sociodemographic and clinical factors related to HCC screening practice, iii) examine the
association of sociodemographic and clinical factors with HCC screening knowledge, and
iv) identify the barriers to HCC screening.

Methods
Study Design and Data Collection
This was a cross-sectional questionnaire study conducted from June to August
2016 at the Shanghai Public Health Clinical Center of Shanghai and Hubei Third People’s
Hospital of Wuhan, China. The source population were patients from outpatient clinics
with a high risk of developing HCC, which comprised of patients with liver cirrhosis and
patients with chronic HBV and/or HCV infection. Based on Chinese liver cancer screening
recommendations, men aged 35 to 65 years and women aged 45 to 65 years were
recruited.11 Patients diagnosed with the above conditions before 2015 were excluded from
the study. Additionally, severely ill patients were not asked to participate.
The questionnaire was designed by the study investigators based on hepatology
experts’ opinions, and previous studies on the screening practices of cervical cancer,
breast cancer and HBV infection [87-89]. In order to examine the feasibility and
appropriateness of the questionnaire, a pilot test was conducted on 30 patients, with 15
from each hospital. The official interviews took place after making adjustments of the initial
questionnaire. Patients from outpatient clinics who met the eligibility criteria were
introduced by their hepatologists to a trained interviewer. After informed consent was
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obtained, an in-person interview was conducted in a private setting within the hospital.
The questionnaire was anonymous and took an average of 10 minutes to complete.

Measures and Assessment
A total of 364 patients responded to the questionnaire and 12 had partial
completions, which were excluded. The questionnaire consisted of three sections. Section
One comprised of 11 multiple-choice and fill-in-the-blank questions, and the
characteristics of interest were age, gender, current region of residence, household
registration, education level, annual household income, health insurance, any immediate
family member with HCC, duration of known hepatitis infection, cirrhosis status, and
presence of comorbidity. Household registration, which classifies individuals as rural or
urban residents, is a system of controlling population migration and determining eligibility
for state-provided welfare and benefits [90]. There are three main types of insurance
programs in China: Urban Employee’s Basic Medical Insurance (UEBMI) covers insurance
for the urban working population, Urban Resident Basic Medical Insurance (URBMI)
provides care to urban residents who are unemployed, and New Rural Cooperative
Medical System (NCMS) provides financial subsidies for rural residents.
The main outcome measure of the study was screening practice. Routine
screening was defined as receiving both serum AFP and abdominal ultrasound at least
every 6 months, irregular screening interval involved screening with both tests on an
inconsistent interval, and patients with incomplete or no screening either never had AFP
test or the combination of AFP and abdominal ultrasound. In section Two, patients were
questioned if they have ever received AFP and abdominal ultrasound. If answered “yes”,
patients were asked how often they received screening and the time of their most recent
screening. If answered “no”, patients were asked to choose the reason (s) or barrier (s)
for not having undergone screening and more than one choice were allowed.
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Section Three consisted of 8 yes-or-no questions and 5 multiple-choice questions
that examined the patients’ knowledge concerning viral hepatitis, HCC, and HCC
screening guidelines. Two of the multiple-choice questions had 2 correct answer choices.
The knowledge score (range: 0-15) was calculated by giving one point for each correct
answer and zero points for an incorrect answer or an answer of “I do not know”. A copy of
the questionnaire can be found in Appendix B.

Statistical Analysis
Data analysis was carried out with SAS 9.4 (SAS, Inc., Cary, NC), using
significance level at P <0.05. Descriptive statistics were performed, and frequencies and
percentages were reported for categorical variables while mean and standard deviation
were presented for the continuous variable. Patients’ sociodemographic factors, clinical
factors and knowledge were compared among the different screening practice groups
using Chi-square or Fisher Exact test for categorical variables and one-way ANOVA for
the continuous variable. All factors were included in a multinominal logistic regression
model with stepwise model selection (P =0.15) to identify the independent predictors for
screening practice. Adjusted odds ratio (OR) and 95% confidence intervals were
generated for variables in the final model.
To investigate the association of knowledge with sociodemographic and clinical
factors, t test, one-way ANOVA and Tukey post hoc test were utilized. In addition, multiple
linear regression analysis was conducted with stepwise model selection (P =0.15) to
examine the independent predictors for knowledge. Model diagnostics for regression were
performed and data satisfied the assumptions in a linear regression model. There was no
evidence of heteroscedasticity and missing covariates, and knowledge score
demonstrated a normal distribution pattern individually and when combined with
covariates.
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This study was approved by the Institutional Review Board at the University of
Nebraska Medical Center and the Ethics Committees of Shanghai Public Health Clinical
Center and Hubei Third People’s Hospital.

Results
Patient Characteristics
A total of 352 valid questionnaires were collected with a response rate of 92%. 156
and 196 patients were recruited from Shanghai and Wuhan, respectively. The majority of
patients were males (71.3%), currently resided in urban regions (85.8%), had urban
household registration (77.6%) and UEBMI health insurance (67.9%), had no immediate
relative diagnosed with HCC (78.7%) and were cirrhotic (62.8%). The mean knowledge
score was 9.0 (SD: 2.8). A total of 176 patients (50.0%) had routine screening, 82 (23.3%)
had irregular screening and 94 (26.7%) had incomplete or no screening. Out of the 94
patients with incomplete or no screening, 83 had received ultrasound only and 11 never
had either AFP or ultrasound. As shown in Table 1, screening practice was significantly
associated with residence (P =0.003), household registration (P =0.003), education level
(P <0.001), annual household income (P <0.001), family history (P =0.027), cirrhosis
status (P =0.017) and knowledge score (P <0.001).

Predictors of HCC Screening Practice
Table 2 shows the results of multinominal logistic regression on factors associated
with screening practice. Education level, family history, cirrhosis status and knowledge
were significantly associated with screening practice. Patients with an education level of
high school and college or above were 2.80 (P =0.002) and 3.94 (P =0.002) times more
likely to receive routine screening, respectively, compared to patients graduated from
middle school or below. Likewise, patients with a degree of high school and college or
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above were 2.72 (P =0.005) and 2.62 (P =0.045) times more likely to receive irregular
screening, respectively. Patients with an immediate family member with HCC were 2.86
(P =0.011) times more likely to undergo routine screening and 2.51 (P =0.033) times more
likely to receive irregular screening compared to patients with no family history with HCC.
Additionally, cirrhotic patients were 2.39 times more likely to have routine screening
compared to patients without cirrhosis (P =0.007). Knowledge was also a significant
predictor; a one-point increase in knowledge score significantly increased the odds of
undertaking routine screening (OR: 1.47; P <0.001) or screening with irregular interval
(OR: 1.18; P =0.013).

Factors Associated with HCC Screening Knowledge
The association between sociodemographic and clinical characteristics with
knowledge was generated from univariate analysis (Table 3). Patients from age group 3544 had better knowledge than patients aged 55-65 years (P =0.003). Patients living in
urban areas (P <0.001) and patients with urban household registration (P <0.001) also
exhibited better knowledge. Moreover, patients with a college education or above had
better knowledge than patients with degrees of high school and middle school or below (P
<0.001). Patients with an annual household income (RMB) of greater than 150K
(approximately U.S. $22K) had better knowledge than patients who earned 40K-80K
(approximately U.S. $6K-12K) and less than 40K (approximately U.S. $6K) (P <0.001).
Additionally, patients with a hepatitis infection of 0-9 years had worse knowledge than
patients with hepatitis infection for 10-19 years and 20 years or more (P <0.001).

Predictors of HCC Screening Knowledge
Table 4 illustrates the results of multiple linear regression on the significant
predictors for knowledge. Patients aged 55-65 years and 45-54 years had knowledge
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score of 1.49 point (P <0.001) and 0.98 point (P =0.010) lower than patients from age
group of 35-44. Female patients scored 0.72 point higher in knowledge score compared
to male patients (P =0.020), and patients living in rural areas had knowledge score of 1.25
points lower than patients living in urban areas (P =0.002). In addition, patients with a
college degree or above had 1.67 points higher in knowledge score than patients with a
middle school degree or below (P <0.001). Patients with annual household income (RMB)
of greater than 150K and 40K-80K scored 1.48 points (P =0.004) and 0.70 point (P =0.041)
higher in knowledge score than patients who earned less than 40K. Furthermore, patients
with a hepatitis infection of 20 years or more and 10-19 years had 1.59 points (P <0.001)
and 0.92 point (P =0.007) higher in knowledge score than patients with hepatitis infection
for 0-9 years.

Specific Knowledge on Viral Hepatitis, HCC, and HCC Screening Guidelines
Questions addressing knowledge are presented in Appendix A. The question with
the highest percentage of overall correct response was “Is excessive alcohol consumption
considered a risk factor for HCC?” (88.1%). The three questions with the lowest
percentage of overall correct responses were “Does hepatitis have to cause cirrhosis
before developing HCC?” (31.3%), “Prior to participation, did you know the purpose of the
liver AFP test?” (39.8%), and “When should patients with chronic hepatitis start to undergo
HCC screening?” (41.2%). As illustrated, patients with routine screening were most likely
to answer each knowledge question correctly.

Barriers to Participate in HCC Screening
The frequencies of self-perceived barriers were analyzed and are described (Table
5). The top five reasons for not receiving HCC screening were “Not aware that screening
for HCC exists” (41.5%), “No symptoms or discomfort” (38.3%), “Lack of recommendation

46
from physicians” (31.9%), “Do not know the benefits of screening” (22.3%), and “Since
HCC is difficult to treat, why bother to undergo screening” (18.1%).

Discussion
To our knowledge, this is the first study to evaluate the practice, knowledge and
barriers for HCC screening among high-risk hospital patients in China. The results showed
that only 50.0% of patients underwent standard routine screening. A meta-analysis
involving 19 published studies on HCC surveillance adherence rate among 16,446 highrisk patients found that the overall adherence was 61.0% [91]. This meta-analysis mainly
comprised of studies from Europe and North America, and surveillance was defined as a
combination of imaging plus AFP [91]. Moreover, retrospective studies on HCC
surveillance conducted in East Asian regions, including Japan, Taiwan and Hong Kong,
demonstrated that adherence rates varied from 15.2% to 79.0% among high-risk hospital
patients [92].
Similar to our findings, a study found that patients with degrees of high school or
college or above had greater odds of undergoing routine screening. Moreover, a study
that investigated the utilization of HCC surveillance among U.S. cirrhotic patients reported
that patients with more than a high school education were more likely to receive regular
HCC screening than patients with less than a high school education [93]. A study
consisting of patients with chronic HBV, conducted in the San Francisco Bay Area and
comprised of 92% Asian populations, found that patients with cirrhosis were more likely to
have optimal HCC screening than patients without cirrhosis [94]. Furthermore, Zhao et al.
found that cirrhotic patients had significantly higher surveillance adherence rates than
patients with chronic HBV [91]. These results support our finding that cirrhosis was a
significant determinant for receiving routine screening. Furthermore, patients with better
knowledge concerning viral hepatitis, HCC, and screening guidelines were more likely to
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be screened. Likewise, a survey that investigated HCC screening practice among San
Francisco healthcare providers with large Asian American populations demonstrated that
better knowledge concerning HCC and surveillance was associated with performing HCC
screening [95].
Our finding indicated that younger patients had better knowledge, and this is
supported by a study conducted in chronic hepatitis patients in Taiwan, which found that
patients’ age was negatively associated with hepatitis knowledge and health perceptions
[8]. Moreover, our results demonstrated that residents residing in rural regions had worse
knowledge, and this was even shown among Chinese healthcare and public health
professionals, in which individuals from rural provinces had worse knowledge about HBV
and liver cancer than those from urban provinces [7]. Studies conducted among hepatitis
patients in Taiwan, general hospital patients in China, and cirrhotic patients at the
University of Michigan have shown that education level was a major factor for
demonstrating better knowledge in hepatitis and HCC [6, 8, 96]; these results are in
accordance with our finding. Additionally, higher annual household income was an
important factor on knowledge; Chen et al. discovered that household income was not
only an important determinant on knowledge, but it was also positively corrected with
perceived susceptibility, benefits, barriers and cues to action [8].
The knowledge question that was mostly missed was “Does hepatitis have to
cause cirrhosis before developing HCC?”, as only 31.3% of the overall population and
25.5% of patients with incomplete or no screening answered it correctly. Although the
majority of patients with HBV or HCV who develop HCC have cirrhosis, HBV and HCV are
able to cause HCC in the absence of cirrhosis [49, 97]. This misconception may have
affected screening practice because patients without cirrhosis may feel safe at the
moment and believe they have another stage to go through before developing HCC. In
addition, 44.9% of patients with routine screening and 63.4% with irregular screening did
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not know the purpose of the liver AFP test before participation in this study. Many patients
underwent AFP simply because they were asked to do so by their hepatologists, but there
was a lack of explanation and education about receiving HCC screening.
“Not aware that screening for HCC exists” was the most common reason for not
having undergone screening, which illustrates a serious deficiency in HCC screening
knowledge. Such lack of knowledge among high-risk patients indicates that insufficient
knowledge and awareness also likely exists in the general Chinese population, which
results in inadequate preventive measures and enables HCC to be prevalent. Another
important barrier was “No symptoms or discomfort”, which was cited as the second most
common reason for refusing cervical cancer screening among women from a region in
China with high cervical cancer incidence [88]. In traditional Chinese culture, visiting
physicians is usually for the purpose of treating and managing illnesses rather than
prevention, putting an emphasis on dealing with health crises over health promotion [98].
Studies that examined cervical, breast, and colon cancer screening practices among
Chinese American women and Chinese immigrants discovered that physician
recommendation was a major factor for screening adherence [99-101]. Likewise in our
study, “Lack of recommendation from physicians” was cited as one of the key reasons for
not participating in screening. Since physicians are often regarded as authoritative figures
in Chinese culture [102], it is crucial for Chinese physicians and healthcare providers to
take the lead and educate patients about the importance of HCC screening. Whereas U.S.
studies on HCC surveillance observed financial reasons to be a substantial barrier for
screening [94, 95], only 16.0% of patients with incomplete or no screening listed financial
difficulty as a barrier in our study. This finding is also consistent with our result that neither
annual household income nor insurance status had a significant impact on screening
practice. The reason could be due to the cost of HCC screening, in which a combination
of AFP and ultrasound is listed to be 90 RMB (approximately U.S. $13) at Shanghai Public
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Health Clinical Center and 200 RMB (approximately U.S. $30) at Hubei Third People’s
Hospital. These prices are reasonable considering household income, and screening cost
becomes even lower with insurance coverage. Other barriers observed included “Do not
know the benefits of screening”, “Since HCC is difficult to treat, why bother undergo
screening”, “Afraid of detecting HCC”, “Lack of time”, “Difficult to access medical facilities”,
“Do not believe that HCC screening is an effective prevention”, and “Not afraid of
developing HCC”. As shown, the majority of the barriers are associated with a lack of
understanding, knowledge and awareness about HCC screening; therefore, there is a
need to bring out public attention and correct these misconceptions. Improving an
individual’s knowledge regarding HCC will likely lead to a change in behavior. Healthcare
professionals and community leaders should provide extensive education to inform highrisk populations about the importance of HCC screening and that screening is beneficial
because treatments for HCC can be offered with early detection. Moreover, it is crucial to
educate high-risk patients about adopting healthy lifestyles and continuously reinforce the
importance of HCC screening.
In China, many HBV carriers are living under a great amount of stress and are
frequently facing discrimination in life and work due to social stigma. Discrimination
against HBV carriers is a major issue in China, and many healthcare services even report
a positive test result to the patient’s school or employer [7]. In addition, it is still a common
belief that HBV is transmittable through eating together and contacts, which underlies the
prejudice against infected individuals [103]. Since social pressure generated from the
society may have deterred high-risk patients from undertaking screening, there is a need
to identity individuals with psychological issues and offer the appropriate counseling,
which could involve providing education regarding HCC, alleviating emotional stress,
managing crisis, recommending lifestyle modifications, and giving encouragements.
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The main strengths of this study are that the response rate was high and the
sample size was large enough to generate statistically meaningful findings; however, this
study is subject to some limitations. Since electronic medical record systems were not
available at the studied institutions, formal verification for data accuracy was not
performed. Although we relied on self-report, quality controls and best efforts were
delivered to assure data collected were reliable. Since our collaborating institutions are
major tertiary hospitals in large urban cities, and because major gaps in economic
development and health disparities exist between urban and rural regions in China [104],
future studies can be carried out in rural and less economically developed regions. It would
be reasonable to assume that screening adherence rate in many economically
impoverished regions in China is lower than the rate observed in our study. Moreover,
since patients who visit healthcare facilities tend to have better health awareness, it would
be of interest to investigate HCC screening practice among high-risk patients from a
community-based setting in China.
Since China alone accounts for half of the liver cancer cases and deaths globally,
understanding the reasons for the lack of HCC screening in high-risk populations could
assist healthcare professionals to develop more effective intervention methods for early
detection. As screening helps to detect HCC at an early stage, effective treatments may
be offered to achieve better chances of survival. Unlike the screening approaches
formulated for certain other cancers, which target the general population, strategies for
improving HCC screening should be different. Our findings suggest that appropriate and
effective educational programs should be established. Chinese healthcare practitioners
and community health promotion leaders should pursue an active role to implement and
utilize educational programs as an intervention to improve high-risk patients’ awareness,
knowledge and perceptions about HCC screening. These educational programs should
target patients with low socioeconomic status, patients who reside in rural areas, as well
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as middle-aged and older patients. Also, professional counseling could be provided to
assist patients with social or psychological issues regarding hepatitis or HCC. In addition,
the approach of entering high-risk patients into disease management programs and
providing automatic reminders could potentially improve screening adherence [105, 106];
this calls for the implementation and adaptation of electronic health record systems in
China. Further studies conducted in multiple diverse areas in China are warranted.
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Table 1. A Comparison of Screening Practice by Sociodemographic Characteristics,
Clinical Characteristics and Knowledge Score (N = 352)
Routine
Screening
(N=176) N (%)
Age group (year)
35-44
33 (18.8)
45-54
65 (36.9)
55-65
78 (44.3)
Gender
Male
117 (66.5)
Female
59 (33.5)
Residence
Urban
160 (90.9)
Rural
16 (9.1)
Household
registration
Urban
145 (82.4)
Rural
31 (17.6)
Education level
Middle school or below
45 (25.6)
High school
71 (40.3)
College or above
60 (34.1)
Household income
<40K
37 (21.0)
40K-80K
66 (37.5)
80K-150K
41 (23.3)
>150K
32 (18.2)
Insurance type
UEBMI
129 (73.3)
URBMI
16 (9.1)
NCMS
12 (6.8)
Out-of-pocket
12 (6.8)
Other
7 (4.0)
Family history
Yes
45 (25.6)
No
131 (74.4)
Hepatitis duration
(year)
0-9
47 (26.7)
10-19
45 (25.6)
≥20
84 (47.7)
Cirrhosis status
Yes
78 (44.3)
No
98 (55.7)
Comorbidity
0
88 (50.0)
1
53 (30.1)
2
23 (13.1)
≥3
12 (6.8)
Knowledge score,
10.1 (2.5)
mean (SD)
*Statistical significance at P <0.05

Irregular
Screening Interval
(N=82) N (%)

Incomplete/No
Screening
(N=94) N (%)

22 (26.8)
24 (29.3)
36 (43.9)

18 (19.2)
33 (35.1)
43 (45.7)

70 (74.5)
24 (25.5)

64 (78.1)
18 (22.0)

71 (86.6)
11 (13.4)

71 (75.5)
23 (24.5)

P
Value
0.57

0.12

0.003*

0.003*
67 (81.7)
15 (18.3)

61 (64.9)
33 (35.1)

25 (30.5)
39 (47.6)
18 (22.0)

55 (58.5)
28 (29.8)
11 (11.7)

22 (26.8)
33 (40.2)
18 (22.0)
8 (11.0)

43 (45.7)
33 (35.1)
13 (13.8)
5 (5.3)

56 (68.3)
10 (12.2)
7 (8.5)
6 (7.3)
3 (3.7)

54 (57.5)
13 (13.8)
16 (17.0)
5 (5.3)
6 (6.4)

19 (23.2)
63 (76.8)

11 (11.7)
83 (88.3)

<0.001*

<0.001*

0.17

0.027*

0.050
24 (29.3)
26 (31.7)
32 (39.0)

40 (42.6)
23 (24.5)
31 (33.0)

27 (32.9)
55 (67.1)

26 (27.7)
68 (72.3)

37 (45.1)
29 (35.4)
10 (12.2)
6 (7.3)
8.6 (2.6)

52 (55.3)
23 (24.5)
14 (14.9)
5 (5.3)
7.4 (2.5)

0.017*

0.78

<0.001*
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Table 2. Multinomial Logistic Regression of the Effect of Sociodemographic
Characteristics, Clinical Characteristics and Knowledge Score on Screening Practice (N
= 352)
Routine Screening vs.
Incomplete/No Screening

Irregular Screening Interval vs.
Incomplete/No Screening

OR (95% CI)

P Value

OR (95% CI)

P Value

Reference
1.56 (0.81, 3.00)

0.18

Reference
0.85 (0.41, 1.78)

0.66

Reference
2.80 (1.45, 5.41)
3.94 (1.67, 9.27)

0.002*
0.002*

Reference
2.72 (1.36, 5.46)
2.62 (1.02, 6.73)

0.005*
0.045*

Reference
2.86 (1.28, 6.40)

0.011*

Reference
2.51 (1.08, 5.82)

0.033*

Reference
2.39 (1.28, 4.46)
1.47 (1.30, 1.67)

0.007*
<0.001*

Reference
1.40 (0.71, 2.76)
1.18 (1.04, 1.35)

0.33
0.013*

Gender
Male
Female
Education level
Middle school or below
High school
College or above
Family history
No
Yes
Cirrhosis status
No
Yes
Knowledge score

*Statistical significance at P <0.05
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Table 3. A Comparison of Knowledge Score by Sociodemographic and Clinical
Characteristics (N = 352)
Knowledge Score

Age group (year)
35-44
45-54
55-65
Gender
Male
Female
Residence
Urban
Rural
Household registration
Urban
Rural
Education level
Middle school or below
High school
College or above
Household income (RMB)
<40K
40K-80K
80K-150K
>150K
Insurance type
UEBMI
URBMI
NCMS
Out-of-pocket
Other
Family history
Yes
No
Hepatitis duration (year)
0-9
10-19
≥20
Cirrhosis status
Yes
No
Comorbidity
0
1
2
≥3
*Statistical significance at P <0.05

Mean

SD

9.9
9.0
8.6

3.0
2.8
2.7

9.0
9.1

2.9
2.6

9.4
7.1

2.7
2.6

9.4
7.7

2.7
2.6

8.0
8.9
10.7

2.6
2.6
2.5

7.8
9.0
9.7
10.7

2.5
2.7
2.8
2.6

9.4
8.8
6.8
9.6
8.8

2.7
2.4
2.5
3.0
3.1

9.2
9.0

3.0
2.7

8.1
9.2
9.6

2.6
2.6
2.9

9.1
9.0

3.0
2.7

9.1
9.2
8.6
9.0

2.9
2.8
2.6
2.8

P Value
0.003*

0.73

<0.001*

<0.001*

<0.001*

<0.001*

<0.001*

0.48

<0.001*

0.58

0.68
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Table 4. Multiple Linear Regression of the Effect of Sociodemographic and Clinical
Characteristics on Knowledge Score (N = 352)
Knowledge Score
βCoefficient
Age group (year)
35-44
45-54
55-65
Gender
Male
Female
Residence
Urban
Rural
Education level
Middle school or below
High school
College or above
Household income (RMB)
<40K
40K-80K
80K-150K
>150K
Hepatitis duration (year)
0-9
10-19
≥20

SE

95% CI

P Value

Reference
-0.98
-1.49

0.38
0.38

(-1.73, -0.24)
(-2.24, -0.75)

0.010*
<0.001*

Reference
0.72

0.30

(0.11, 1.31)

0.020*

Reference
-1.25

0.41

(-2.06, -0.45)

0.002*

Reference
0.46
1.67

0.33
0.41

(-0.18, 1.10)
(0.87, 2.47)

0.16
<0.001*

Reference
0.70
0.65
1.48

0.34
0.44
0.51

(0.03, 1.37)
(-0.22, 1.51)
(0.48, 2.47)

0.041*
0.14
0.004*

Reference
0.92
1.59

0.34
0.31

(0.25, 1.59)
(0.98, 2.21)

0.007*
<0.001*

*Statistical significance at P <0.05
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Table 5. Barriers towards Participation in HCC Screening among Patients Who had
Incomplete or No Screening (N = 94)
Barriers
1. Not aware that screening for HCC exists
2. No symptoms or discomfort
3. Lack of recommendation from physicians
4. Do not know the benefits of screening
5. Since HCC is difficult to treat, why bother undergo screening
6. Financially difficult to afford screening
7. Afraid of detecting HCC
8. Lack of time
9. Difficult to access medical facilities
10. Do not believe that HCC screening is an effective prevention
11. Not afraid of developing HCC

Frequency
39 (41.5%)
36 (38.3%)
30 (31.9%)
21 (22.3%)
17 (18.1%)
15 (16.0%)
13 (13.8%)
12 (12.8%)
7 (7.4%)
5 (5.3%)
3 (3.2%)
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ADHERENCE AND PERCEIVED BARRIERS TO ORAL ANTIVIRAL THERAPY FOR
CHRONIC HEPATITIS B
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Abstract
Background: Globally, of the 248 million people chronically infected with the
hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs)
have been approved for the treatment of chronic HBV in China.
Objectives: The aims of this study were to determine rates of adherence to NUC
therapy in patients with chronic HBV, to identify the self-perceived barriers to adherence,
and to examine the factors associated with adherence.
Methods: Questionnaire-based interviews were administered among Chinese
patients with chronic HBV at hepatology clinics of a tertiary hospital in the city of Wuhan,
China. Adults aged 18 years or older prescribed with NUCs were recruited and interviewed
to complete a 27-item questionnaire in a private setting, and adherence was measured
using the Morisky Medication Adherence Scale (MMAS-8).
Results: Among 369 participants, only 16.5% had high adherence (score of 8),
32.2% had medium adherence (score of 6 to <8), and 51.2% were measured with low
adherence (score of <6). A logistic regression model was used to determine the factors
associated with medication adherence. Significant predictors of high adherence consisted
of urban residency, non-cirrhotic status, not using prescribed pills other than HBV
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medications, and reminders from family members. The five most common reasons for
skipping NUCs were that medication(s) are expensive (48.7%), forgetfulness (45.1%),
have experienced or worry about potential side effects (19.8%), do not want others to
know about my medication(s) usage (18.5%), and ran out of pills and do not have time to
refill (15.9%).
Conclusions: This study revealed that adherence rates to oral antiviral therapy
were far from optimal. Healthcare providers should actively inform and educate patients
about the importance of adherence and the consequences for skipping NUCs.
Additionality, the government should enter into negotiations with the generic drug
manufacturers of entecavir to obtain less costly drug.

Introduction
HBV infection is endemic in China. Globally, China is among the countries with a
high prevalence of HBV infection. The biggest health concerns of HBV infection are risks
associated with chronic hepatitis, including cirrhosis, liver failure and HCC [107]. It is
estimated that 85% of HCC cases in China are HBV-related [31], and China accounts for
half of the total number of liver cancer cases and deaths worldwide [4]. Currently, five oral
nucleot(s)ide analogs (NUCs), conventional interferon alpha (IFN-α), and two formulations
of pegylated interferon alpha (PEG-IFNα) have been approved for treating chronic HBV
infection in China [54].
Adherence to antiviral therapy is fundamental for the clinical management of
patients with chronic HBV [108, 109]. Long-term viral suppression was found to be
associated with histologic improvement in the reduction of fibrosis and ultimately
regression of cirrhosis [110]. Furthermore, a study has demonstrated that adult patients
with chronic HBV need over two years of NUC treatment to reduce risk of cirrhosis, HCC
or HBV-related death [111]. In order to achieve and maintain virologic suppression, avoid
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virologic breakthrough, and attain undetectable levels of HBV DNA, optimal medication
adherence is essential [112]. Antiviral therapy functions to prevent, delay, and reverse
disease progression, leading to improved disease management and ultimately result in
better survival [113].
A limited number of studies have utilized questionnaires to investigate the
adherence to HBV antiviral therapy and factors associated with adherence [58-60];
however, these studies were limited to small sample sizes. Additionally, there is a lack of
research focused to assess the self-perceived barriers and facilitators for adherence to
HBV antiviral therapy. Since China has a high prevalence of HBV infection, it is crucial to
understand the adherence and obstacles for HBV treatment using a validated instrument.
Findings generated from this study could potentially be utilized in developing strategic
preventive measures to improve medication adherence in regions of the world with a high
prevalence of HBV infection. The aims of this study were to i) determine rates of
adherence to NUC antiviral therapy using the Morisky Medication Adherence Scale in
Chinese patients with chronic HBV, ii) identify the self-perceived barriers to NUC
adherence, and iii) investigate the impact of sociodemographic and clinical factors, as well
as treatment-related factors and perceptions of disease on NUC adherence.

Methods
Study design and data collection
This cross-sectional study was conducted from February to May 2017 at the
Department of Hepatology of Hubei Third People’s Hospital, Wuhan, China. The Hubei
Third People’s Hospital is a large tertiary hospital with areas in medicine, research,
teaching, prevention and rehabilitation. It serves as the national base of standardized
residency training and the national base of clinical trials for drug development. The study
utilized a structured questionnaire, which was designed based on the opinions’ from
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experts in hepatology and previous studies on HBV medication adherence [58, 59]. The
source population comprised of chronic HBV patients who were prescribed with one or
more NUCs, and eligible participants consisted of adults aged 18 years or older. Patients
co-infected with HCV), hepatitis D or human immunodeficiency virus, pregnant patients,
and patients prescribed with NUCs less than three months ago were excluded. A pilot test
of 30 patients was conducted to determine the feasibility and suitability of the
questionnaire, and adjustments of the questionnaire were made accordingly. An interviewbased, rather than a self-administered questionnaire was conducted to reduce the
likelihood of participants skipping questions. Informed consent was obtained from all
participants and in-person interviews were conducted in a private setting by a hepatologist
in the hepatology clinics.

Measures and assessment
The questionnaire comprised of four sections. Section I consisted of 9 multiplechoice and fill-in-the-blank questions concerning basic sociodemographic and clinical
information. The factors of interest included age, gender, current region of residence,
education level, annual household income, medical insurance status, duration of known
HBV infection, liver cirrhosis status, and the presence of other chronic diseases. In China,
three main types of social medical insurance programs have been established: Urban
Employee’s Basic Medical Insurance (UEBMI) works to cover insurance for the urban
working population, Urban Resident Basic Medical Insurance (URBMI) provides care for
the unemployed urban residents, and New Rural Cooperative Medical System (NCMS)
provides financial subsidies for residents from rural regions [114].
Medication adherence was assessed by the 8-item Morisky Medication Adherence
Scale (MMAS-8) in Section II of the questionnaire [115]. The MMAS-8 is a simple, reliable,
and widely used instrument for determining adherence to prescribed medications [116].
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The MMAS-8 has been demonstrated to be useful in identifying low adherence in clinical
settings [117]. Moreover, a previous study has utilized the MMAS-8 to examine adherence
to HBV treatment [118]. The Morisky Scale is comprised of 8 questions (score range: 0 to
8), with each item measuring a specific medication adherence behavior. The first seven
items are Yes-or-No questions and the last item has five options. Adherence levels of high,
medium, and low are defined with MMAS-8 scores of 8 points, 6 to <8 points, and <6
points, respectively. The validated Chinese translation was provided by Prof. Donald E.
Morisky, as well as permission to use this scale. In Section III of the questionnaire, patients
with moderate or low adherence were asked to choose the barrier(s) for taking NUCs or
reason(s) for skipping NUCs.
The last section comprised of 10 questions concerning treatment regimen and
patient perceptions. Treatment-related questions consisted of type of NUC taken, duration
of current antiviral therapy, use of other medications for treating HBV, number of other
prescribed pills taken daily (exclude all medications used for HBV treatment), follow up
regularly at the clinic, understanding the physicians’ recommendations, use of memory
aids (e.g. clock alarm, phone alarm), and reminders from family members. In addition,
participants were interviewed about their perceptions of disease condition and current
health condition in general. The entire questionnaire can be found in Appendix C.

Statistical analysis
Data collected were coded and analyzed using SAS 9.4 (SAS Institute Inc., Cary,
NC). A value of P < .05 in a two-tailed test was considered statistically significant.
Descriptive statistics were performed, and variables were expressed as frequencies and
percentages. The association of sociodemographic and clinical factors, as well as
treatment-related factors and perceptions of disease with medication adherence levels
were examined using χ2 test or Fisher Exact test. A multinominal logistic regression model
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with stepwise model selection (inclusion with P < .10) was built to determine the
independent predictors for medication adherence, and all factors from univariate analysis
were inserted into the model. The adjusted odds ratio (OR) and 95% confidence intervals
(CI) were generated in the final model.

Results
Patient characteristics
A total of 369 valid questionnaires were collected, with a response rate of 92.5%.
The mean age of the participants was 49.1 ± 13.3 years, and the average duration of
known HBV infection and current antiviral therapy were 12.7 ± 9.4 years and 64.5 ± 55.4
months, respectively. The majority of patients were males (65.3%), resided in urban
regions (80.8%), graduated with a highest degree from high school (52.9%), had annual
household income of 80K RMB (USD ~$12.3K) or lower (77.0%), had the UEBMI medical
insurance (68.6%), were non-cirrhotic (68.0%), and did not present other chronic diseases
(60.7%) (Table 6). A variety of treatment regimens were prescribed, with 337 patients on
NUC monotherapy and 32 patients on NUC combination therapy. The majority of patients
received entecavir (n = 224, 60.7%), followed by adefovir (n = 100, 27.1%), lamivudine (n
= 45, 12.2%), telbivudine (n = 31, 8.4%) and tenofovir (n = 1, 0.3%). In addition, 28 patients
(7.6%) received entecavir plus adefovir, and 4 patients (1.1%) received lamivudine plus
adefovir.

Medication adherence rates
Adherence rates were determined using the Morisky Medication Adherence Scale.
Based on the MMAS-8 scoring system, a total of 61 patients (16.5%) had high adherence,
119 patients (32.2%) exhibited medium adherence, and 189 patients (51.2%) were
measured with low adherence. A further analysis of the MMAS-8 data showed that overall,
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41.2% of patients stated that they sometimes forget to take medication(s), and 34.7%
reported of having missed taking medication(s) sometime within the past two weeks. A
number of patients (15.2%) reported to have cut back or stopped taking medication(s)
without telling their doctors because they felt worse, or because they felt the symptoms
were under control (19.8%). Moreover, 89 patients (24.1%) reported of sometimes
forgetting to bring along medication(s) when traveling or leaving home. The vast majority
of patients (94.6%) took their medication(s) yesterday, but most patients (52.3%) felt that
it is a hassle to stick with their current treatment plan. When asked about ‘how often do
you have difficulty remembering to take all your antiviral medication(s)?’, 30.9%
responded never/rarely, 27.1% once a while, 31.2% sometimes, 7.9% usually, and 3.0%
all the time.

Factors associated with medication adherence
The association of patient sociodemographic and clinical factors with medication
adherence was generated from univariate analysis. As shown in Table 6, adherence was
significantly associated with region of residence (P < .001), education level (P < .001),
annual household income (P = .003), type of medical insurance (P < .001) and cirrhosis
status (P < .001). Patients with education level of college or above, annual household
income of greater than 150K RMB (USD ~$23K), the UEBMI medical insurance, as well
as patients without cirrhosis and resided in urban regions were more likely to have high
adherence. Table 7 presents the association of treatment-related factors and perceptions
of disease with medication adherence. Adherence was significantly associated with
duration of current antiviral therapy (P =.02), number of other prescribed pills taken daily
(P =.016), follow up regularly at the clinic (P =.016), reminders from family members (P
=.049), and perception of current health condition (P =.021). As shown, patients with a
shorter duration of current treatment at 0–24 months, not using other prescribed pills,
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followed up regularly at the clinic, received reminders from family members, and perceived
their current health condition to be very good were more likely to have high adherence.

Predictors of medication adherence
Table 8 illustrates the results from logistic regression analysis on the determinants
of medication adherence. Region of residence, cirrhosis status, number of other
prescribed pills taken daily, and reminders from family members were significant
predictors of adherence to NUCs. Patients residing in urban regions were 4.88 (95% CI:
1.75–13.51; P =.002) times more likely of having high adherence as opposed to low
adherence when compared to patients from rural regions. Likewise, patients without
cirrhosis were 3.17 (95% CI: 1.26–7.95; P =.014) times more likely to have high adherence
compared to cirrhotic patients. Additionally, patients receiving reminders from family
members were 3.13 (95% CI: 1.53–6.41; P =.002) times more likely to belong to the high
adherence group. Compared to patients taking 2 or more other prescribed pills daily, those
not using other prescribed pills were more likely to exhibit high adherence versus medium
(OR: 0.22; 95% CI: 0.05–0.92; P =.038) or low adherence (OR: 0.18; 95% CI: 0.05–0.73;
P =.017).

Perceived barriers toward medication adherence
The frequencies of self-perceived barriers were analyzed and are described in
Table 9. The top five reasons for skipping NUCs were that ‘Medication(s) are expensive
and difficult to afford’ (48.7%), ‘Forgetfulness’ (45.1%), ‘Have experienced or worry about
potential side effects’ (19.8%), ‘Do not want others to know about my medication(s) usage’
(18.5%), and ‘Ran out of pills and do not have time to refill’ (15.9%).

Discussion
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To our knowledge, this is the largest study utilizing self-report questionnaires to
access the adherence and self-perceived barriers to HBV oral antiviral therapy. Based on
our findings, adherence to NUCs among patients with chronic HBV was found to be very
poor, with 51.2% of patients reported to have low adherence. In comparison, a similar
study that utilized structured questionnaires and conducted in Australia found that 74.1%
of patients reported an adherence rate of 100% [59], while 66% and 52% of patients in
similar studies conducted in the United States and the Netherlands were measured with
an adherence rate of 90% [58, 60]. In contrast, only 16.5% of patients from this study
scored an adherence of 100%. Chotiyaputta et al. [58] observed that 73% of patients
reported they did not miss a single dose of medication during the past 30 days, whereas
we found that just 65.3% of patients did not miss taking medication(s) during the past 2
weeks. Furthermore, rates of high adherence reported in secondary studies that used
pharmacy and medical records were also significantly higher than rate observed in our
study [108, 119-121].
It is widely known that major gaps in the economic development and health
disparities exist between urban and rural regions in China [122]. Our findings
demonstrated that urban residents were significantly more likely to have high adherence
compared to residents from rural regions. In China, rural patients with chronic HBV often
have issues in accessing quality health services due to the lack of specialized clinical
services established in rural areas [123]. The majority of quality hospitals are located in
the urban regions with better trained healthcare professionals and more advanced
technology [124]. Furthermore, HBV has been considered as an economically
catastrophic disease, and costs of treatment are a major burden for rural patients [123].
An estimated figure has shown that less than 5% of rural patients are able to afford one
year of treatment as opposed to 40% of patients in more developed regions [123]. In
addition to issues concerning accessibility and costs of treatment, Chinese patients in rural
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regions also have poor health awareness; many infected-individuals are unaware of their
HBV infection until symptoms appear [125].
The finding that cirrhotic patients were less adherent to NUCs may be explained
by that patients who had better treatment adherence were less likely to develop cirrhosis.
Furthermore, our results illustrated that patients taking 2 or more other prescribed pills on
a daily basis were cited to be more likely of having low adherence. Four studies that
investigated medication nonadherence among elderly populations prescribed with various
medications have shown that a greater number of drugs was associated with worse
adherence [126]. In a large-scale study, researchers examined the effect of previous
prescription burden on adherence rates when antihypertensive or lipid-lowering therapy
was added, and found that rates dropped to 41%, 30% and 20% among patients who
received 0, 2, and 10 or more previous medications, respectively [127]. Polypharmacy is
associated with nonadherence due to a number of factors, including regimen complexity,
time and commitment, treatment costs, financial reimbursement, difficulty in managing coexisting illnesses, side effects, multiple prescribers, access to care, etc. [128].
Consistent with our findings, numerous studies have found a positive relationship
between family support interventions and medication adherence [129]. A lack of family
and social support has shown to be a predictive factor of nonadherence among patients
treated for chronic illnesses [128], and research on the adherence to type II diabetes
treatment demonstrated that family support was the strongest predictor of adherence [130].
Results generated from univariate analysis indicated that higher annual household income
was significantly associated with better adherence, and Chotiyaputta et al. [58] also
observed similar result. In contrast, while studies have observed that patients with poor
adherence were more likely to be younger [58, 60, 121], an association between age and
adherence was not found in this study, which may be explained by racial and ethnic
differences in the study populations.
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‘Medication(s) are expensive and difficult to afford’ was the most common reason
for skipping NUCs. Over 60% of patients in this study were prescribed with entecavir,
which is known for its higher cost and unaffordability to many Chinese patients. However,
research has shown that entecavir is still more cost-effective than other NUCs [131]. One
study evaluated the cost-effectiveness of NUCs in China, and assessed the thresholds at
which the drugs would be cost-saving to the national treatment program [38]. The
investigators found that generic entecavir would be the most cost-effective therapy unless
the cost of tenofovir drops. Currently, several pharmaceutical companies in China are
producing generic versions of entecavir, and the lowest reported price is at $1,258 (~8,556
RMB) per person-year or $105 (~714 RMB) per person-month [132]. Additionally, one
study that estimated the cost of manufacturing generic entecavir at a minimum target price
found that generic entecavir could actually be produced at $36 (~245 RMB) per personyear or $3 (~20 RMB) per person-month, which is substantially lower than the current price
[133]. Since the patent for entecavir has expired, it would be cost-effective for the
government to enter into negotiations with generic drug manufacturers of entecavir to
obtain a less costly drug. Within a competitive market, an affordable and large-scale
treatment system could provide immense health benefits to patients with chronic HBV.
Another common barrier of medication adherence was ‘Forgetfulness’, which was
cited as the main reason for skipping NUCs in the study conducted in Australia [134].
Forgetfulness can be partly dealt through providing reminders, such as from families and
close friends, and the use of alarm clocks or automated text messages [134]. Nonetheless,
forgetfulness can be influenced by cognitive factors [59], including a lack of awareness
and knowledge concerning the health risks associated with disease condition. Therefore,
healthcare providers should actively inform and educate patients about the importance of
adhering to antiviral therapy and the potential consequences for skipping NUCs. One
study based on a review of medical records of 69 immigrant patients in Chicago

68
discovered that concerns about the long-term safety of NUCs was cited as one of the main
barriers to treatment initiation and one of the main reasons for treatment discontinuation
[120]. Likewise in our study, ‘Have experienced or worry about potential side effects’ was
identified as the third most common barrier to NUC adherence. This illustrates a
misconception about NUCs; even though treatment of chronic HBV can often be life-long,
NUCs are generally safe and well-tolerated by patients [135]. Furthermore, a large number
of patients cited ‘Do not want others to know about my medication(s) usage’ as a perceived
barrier. In China, patients with chronic HBV are living under a great amount of emotional
distress and often face discrimination in life and work. Although HBV check-ups for
employment and school enrollment have been banned since 2010, some employers still
request job applicants to disclose HBV test results [136]. As a result, fear of disclosing
HBV status may have negatively affected adherence to treatment. Therefore, with the help
of psychiatrists and clinical psychologists, it would be beneficial to identify patients with
psychological and emotional issues and offer the appropriate counseling, which would
consist of alleviating emotional stress, overcoming fear, managing crises, and giving
encouragements. Furthermore, ‘Ran out of pills and do not have time to refill’, ‘Feel better
already and do not think it is necessary to continue’ and ‘Multiple medications are taken
daily, difficult to track dose’ were other barriers that had an impact on NUC adherence.
Nevertheless, these barriers were not cited as common reasons for skipping NUCs
reported by Giang et al. [59].
This study is subject to certain limitations that should be addressed. As a crosssectional study, significant association between the factors of interest and outcome can
be difficult to interpret, and causality cannot be established as correlation does not imply
causation. For instance, non-cirrhotic status was a significant predictor of high adherence,
but it is difficult to determine whether this was because better NUC adherence served to
prevent adherent patients from developing cirrhosis, or that patients without cirrhosis tend
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to have better adherence. Furthermore, a meta-analysis consisting of studies on NUC
adherence indicated that studies rely on patient self-report may to subject to
overestimation when compared to secondary studies using data from pill count and
pharmacy refill claims [108]. The potential inflation in reporting may be a result of reporting
bias. Lastly, since China is a culturally and economically diverse nation, findings
generated from this study are subject to geographical limitations and should be taken into
account when making application of the results in different parts of the world as well as in
different regions of China.
The finding of poor medication adherence among Chinese patients taking NUCs
should generate public attention, and calls for healthcare providers to work collaboratively
with researchers and community health leaders to develop more effective interventional
methods to improve NUC adherence. These interventional programs should target
patients from rural regions, patients with low socioeconomic status, cirrhotic patients, and
patients prescribed with multiple medications. Additionally, patients with severe emotional
distress or at risk for mental disorders should be identified and be provided with
professional counseling to cope with social and psychological issues. Further studies
should focus to investigate the efficacy and impact of medication adherence on viral
suppression, and the rate of adherence needed to prevent antiviral resistance in Chinese
patients with chronic HBV.
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Table 6. A comparison of adherence to HBV antiviral therapy by patient sociodemographic
and clinical characteristics (n = 369).
High
Adherence
(n=61) n (%)

Characteristics

Medium
Adherence
(n=119) n (%)

Low
Adherence
(n=189) n (%)

Total
Count
(n=369)

Age group (years)
18–39
40–49
50–59
≥60

.07
14 (15.2)
21 (20.6)
11 (13.6)
15 (16.0)

34 (37.0)
39 (38.2)
26 (32.1)
20 (21.3)

44 (47.8)
42 (41.2)
44 (54.3)
59 (62.8)

92
102
81
94

36 (14.9)
25 (19.5)

78 (32.4)
41 (32.0)

127 (52.7)
62 (48.4)

241
128

55 (18.5)
6 (8.5)

110 (36.9)
9 (12.7)

133 (44.6)
56 (78.9)

298
71

9 (11.4)
32 (16.4)
20 (21.1)

18 (22.8)
49 (25.1)
52 (54.7)

52 (65.8)
114 (58.5)
23 (24.2)

79
195
95

15 (15.0)
29 (15.8)
13 (19.7)
4 (21.1)

21 (21.0)
59 (32.1)
28 (42.4)
11 (57.9)

64 (64.0)
96 (52.2)
25 (37.9)
4 (21.1)

100
184
66
19

51 (20.2)
3 (13.0)
3 (4.7)
2 (18.2)
2 (11.1)

89 (35.2)
8 (34.8)
8 (12.5)
3 (27.3)
11 (61.1)

113 (44.7)
12 (52.2)
53 (82.8)
6 (54.6)
5 (27.8)

253
23
64
11
18

36 (34.0)
56 (38.6)
27 (22.9)

50 (47.2)
67 (46.2)
72 (61.0)

106
145
118

25 (21.2)
94 (37.5)

84 (71.2)
105 (41.8)

118
251

82 (36.6)
24 (25.0)
13 (26.5)

103 (46.0)
59 (61.5)
27 (55.1)

224
96
49

Gender

.51

Male
Female
Region of residence
Urban
Rural
Education level
Middle school or below
High School
College or above
Household income (RMB)
<50K
50K–80K
80K–150K
>150K
Type of insurance¶
UEBMI
URBMI
NCMS
OOP
Others

<.001

<.001

.003

<.001

Duration of HBV infection (years)
0–5
20 (18.9)
6–15
22 (15.2)
>15
19 (16.1)
Cirrhosis status
Yes
9 (7.6)
No
52 (20.7)
Other chronic diseases
0
39 (17.4)
1
13 (13.5)
≥2
9 (18.4)
¶Abbreviation:

.06

<.001

0.12

UEBMI, Urban Employee’s Basic Medical Insurance; URBMI, Urban Resident

Basic Medical Insurance,
pocket.

P
Value

NCMS, New Rural Cooperative Medical System; OOP, out-of-
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Table 7. A comparison of adherence to HBV antiviral therapy by treatment-related
characteristics and perceptions of disease (n = 369).

Characteristics

High
Adherence
(n=61) n (%)

Duration of current therapy (months)
0–24
21 (27.6)
25–60
23 (13.3)
>60
17 (14.2)
Use of other medications to treat HBV
Yes, Chinese medicine
20 (14.4)
Yes, Western medicine
2 (13.3)
No
39 (18.1)
Number of prescribed pills taken daily¶
0
49 (19.8)
1
8 (13.1)
≥2
4 (6.6)
Regularly visit clinic for HBV
Yes
55 (17.5)
No
6 (10.9)
Understand what the physicians
recommend
Yes
56 (17.1)
No
5 (11.9)
Use of memory aids
Yes
4 (10.8)
No
57 (17.2)
Reminders from family members
Yes
28 (21.7)
No
33 (13.8)
Perception of disease conditionδ
Severe
6 (16.7)
Moderate
24 (15.7)
Mild
26 (16.5)
Don’t know
5 (22.7)
Perception of current health condition
Very good
5 (45.5)
Good
20 (17.5)
Fair
30 (14.6)
Poor
6 (15.8)
¶ HBV

Medium
Adherence
(n=119) n (%)

Low
Adherence
(n=189) n (%)

Total
Count
(n=369)

26 (34.2)
64 (37.0)
29 (24.2)

29 (38.2)
86 (49.7)
74 (61.7)

76
173
120

41 (29.5)
6 (40.0)
72 (33.5)

78 (56.1)
7 (46.7)
104 (48.4)

139
15
215

.003

.64

.002
89 (36.0)
14 (23.0)
16 (26.2)

109 (44.1)
39 (63.9)
41 (67.2)

247
61
61
.016

108 (34.4)
11 (20.0)

151 (48.1)
38 (69.1)

314
55
.62

106 (32.4)
13 (31.0)

165 (50.5)
24 (57.1)

327
42

16 (43.2)
103 (31.0)

17 (46.0)
172 (51.8)

37
332

45 (34.9)
74 (30.8)

56 (43.4)
133 (55.4)

129
240

.28

.049

.12
9 (25.0)
41 (26.8)
62 (39.2)
7 (31.8)

21 (58.3)
88 (57.5)
70 (44.3)
10 (45.5)

36
153
158
22
.021

3 (27.3)
43 (37.7)
67 (32.5)
6 (15.8)

3 (27.3)
51 (44.7)
109 (52.9)
26 (68.4)

medications are not included.

δParticipants

P
Value

who answered ‘don’t know’ were excluded from analysis.

11
114
206
38
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Table 8. Multinomial logistic regression of the effect of sociodemographic characteristics,
clinical characteristics, treatment-related characteristics and perceptions of disease on
adherence to HBV antiviral therapy (n = 369).

Characteristics

Region of residence
Rural
Urban

High Adherence
versus
Medium Adherence
OR (95% CI)

P Value

OR (95% CI)

P Value

Reference
0.79 (0.24, 2.61)

.70

Reference
4.88 (1.75, 13.51)

.002

.58

Reference
3.17 (1.26, 7.95)

.014

.83
.038

Reference
0.45 (0.17, 1.20)
0.18 (0.05, 0.73)

.11
.017

.31

Reference
3.13 (1.53, 6.41)

.002

Cirrhosis status
Yes
Reference
No
1.33 (0.48, 3.65)
Number of prescribed pills taken daily¶
0
Reference
1
0.89 (0.30, 2.61)
≥2
0.22 (0.05, 0.92)
Reminders from family members
No
Reference
Yes
1.44 (0.71, 2.93)
¶ HBV

medications are not included.

High Adherence
versus
Low Adherence
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Table 9. Perceived barriers toward compliance to HBV antiviral therapy among patients
with medium and low adherence in rank order (n = 308).
Barriers

n (%)

1. Medication(s) are expensive and difficult to afford

150 (48.7)

2. Forgetfulness

139 (45.1)

3. Have experienced or worry about potential side effects
4. Do not want others to know about my medication(s) usage
5. Ran out of pills and do not have time to refill

61 (19.8)
57 (18.5)
49 (15.9)

6. Feel better already and do not think it is necessary to continue

41 (13.3)

7. Multiple medications are taken daily and cannot keep track of dose for
each
8. Cannot tell the difference between taking/not taking medication(s)
9. Insurance does not provide coverage when cost exceeds the limit
10. Emotionally distressed about disease condition and have no desire to
continue
11. Physician did not inform me about the importance of taking
medication(s) timely
12. Difficulty swallowing

37 (12.0)
33 (10.7)
32 (10.4)
15 (4.9)
7 (2.3)
3 (1.0)
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CHAPTER IV
SURGICAL DELAY IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS
WITH HEPATOCELLULAR CARCINOMA
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10.1007/s11605-018-3925-4.

Abstract
Background: Hepatocellular carcinoma (HCC) is one of the fastest growing
causes of cancer-related death in the United States. Studies that investigated the impact
of HCC therapeutic delays are limited to single centers, and no large-scale database
research has been conducted. This study investigated the association of surgical delay
and survival in HCC patients.
Methods: Patients underwent local tumor destruction and hepatic resection for
stage I-III HCC were identified from the 2004-2013 Commission on Cancer’s National
Cancer Database. Surgical delay was defined as >60 days from the date of diagnosis to
surgery. Generalized linear mixed model assessed the demographic and clinical factors
associated with delay, and frailty Cox proportional hazards analysis examined the
prognostic factors for overall survival.
Results: 12,102 HCC patients met the eligibility criteria. Median wait time to
surgery was 50 days (interquartile range: 29–86), and 4,987 patients (41.2%) had surgical
delay. Delayed patients demonstrated better 5-year survival for local tumor destruction
(29.1% vs. 27.6%; P=.001) and resection (44.1% vs. 41.0%; P=.007). Risk-adjusted model
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indicated that delayed patients had a 7% decreased risk of death (HR: 0.93; 95% CI: 0.87–
0.99; P=.027). Similar findings were also observed using other wait time cutoffs at 50, 70,
80, 90 and 100 days.
Conclusions: A plausible explanation of this finding may be case prioritization, in
which patients with more severe and advanced disease who were at higher risk of death
received earlier surgery, while patients with less aggressive tumors were operated on later
and received more comprehensive preoperative evaluation.

Introduction
In the United States, hepatocellular carcinoma (HCC) is one of the fastest growing
causes of cancer-related death, and death rates have doubled since the mid-1980s [11].
According to 2017 estimates, there were 40,710 newly diagnosed cases and 28,920
associated deaths of liver cancer in the U.S [22]. The detrimental effect of HCC is indicated
by its poor survival, with an estimated 5-year relative survival rate of just 17.7% [12]. Earlystage HCC patients can receive potentially curative options, such as liver transplantation,
partial resection, and radiofrequency ablation (RFA) [36]. Due to the shortage of liver
donors with potential recipients outnumbering donors, and a lack of access to
transplantation centers [64], many surgeons perform resection and locoregional therapies
as alternative treatments or as bridging therapy to prevent tumor progression [137].
Due to the poor prognosis of HCC, it is necessary to initiate early active therapy
once the disease is diagnosed. Furthermore, the natural course of untreated HCC is
associated with advanced cancer staging [138]. The transition from diagnosis to treatment
is complex and often requires multiple steps and many healthcare providers [139]. This
transition involves decision-making on the optimal treatment, patient referral, appointment
scheduling, preoperative clearance, and patient adherence in undertaking treatment [13].
These steps can occur in isolation or in combination, which often makes timely intervention
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difficult to accomplish. An obstacle that occurs in any stage could result in treatment delay.
A systematic review consisting of 177 studies investigated the association between time
to diagnosis, treatment, and clinical outcomes across different cancer types [140].
Although there are conflicting findings on the impact of delay from diagnosis to treatment
in various malignancies, a large number of cancer studies have reported that prolonged
wait time to surgery was associated with less favorable outcomes [140].
Currently, there are no established guidelines for defining delay in HCC-directed
surgery or the optimal time interval from diagnosis to surgery. Several studies have
investigated the clinical impact of HCC therapeutic delays or prolonged wait time on
outcomes in patients who underwent locoregional therapies [14-16], resection [17, 18],
and with different treatments analyzed altogether [13, 19]. Nevertheless, the findings
produced inconsistent results and most were restricted to single centers with limited
sample sizes. As of this date, no large-scale database analysis has been conducted on
this matter. To address the aforementioned gap, we conducted a retrospective study
utilizing data drawn from the Commission on Cancer’s National Cancer Database (NCDB)
2004–2013 Participant User Data File for liver cancer. The main objectives of this study
were to identify the demographic and clinical factors associated with delay in HCC surgical
treatment, and to evaluate the relationship between surgical delay and long-term survival
in HCC patients.

Methods
Data source and study population
The NCDB is a nationwide, facility-based, comprehensive clinical oncology dataset
that consists of 70% of newly diagnosed malignancies in the United States [141]. The
NCDB is a jointly sponsored program of the American College of Surgeons Commission
on Cancer (CoC) and the American Cancer Society. It is sourced from hospital registry
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data that are collected prospectively from more than 1,500 commission-accredited cancer
programs in the U.S. and Puerto Rico, and contains more than 34 million historical records
of adult patients 18 years old or older [141].
Cases selected for analysis were comprised of cancers reported with International
Classification of Diseases for Oncology, 3rd edition (ICD-O-3), topographical code C22.0
(liver) and histopathologic types 8170–8175 (hepatocellular carcinoma) (n=118,800). The
study solely consisted of cases with a malignant primary tumor site, and cases were
staged in accordance with the 6th and 7th editions of the American Joint Committee on
Cancer (AJCC) staging system. Based on the eligibility criteria (Figure 3 summarizes the
patient selection process), we included HCC patients surgically treated with local tumor
destruction (LTD) and hepatic resection. For disease stage, the analysis was limited to
cases with stage I to III disease. Clinical stage was given priority and pathologic stage was
used when clinical stage was not reported. Patients with a sequence number other than
“00” or “01” were excluded. Sequence code “00” indicates that the patient had only one
lifetime cancer diagnosis and “01” represents that the reported tumor was the first of
multiple diagnoses. Since wait time to surgery was based on the number of days between
date of diagnosis to date of the most definitive surgery, patients who received cancerdirected surgery prior to undergoing definitive surgery were excluded. We further excluded
patients whose wait time between diagnosis and definitive surgery was unavailable, as
well as patients with definitive surgery performed past two years after diagnosis to
eliminate for possible outliers. Cases were excluded if the diagnosis date was the same
as date of definitive surgery, which indicated an emergent procedure or coding error. The
final study population consisted of 12,102 patient-level observations. Survival data were
available for patients diagnosed between 2004 and 2012 (n=10,285), and those
diagnosed in 2013 were not included in survival analysis (n=1,817).

78
Data definitions and coding
Wait time to surgery was classified as a dichotomous outcome of “non-delayed”
and “delayed” groups. The date of diagnosis was coded as that of the most definitive
method of diagnostic confirmation, and diagnosis was primarily based on histologic or
cytologic confirmation of biopsy specimens (77.1%) and imaging techniques (20.1%).
Based on the data distribution and proportionality, and a review of similar studies that
defined delay in patients who underwent locoregional therapies or resection [14, 19, 142],
delay in surgery was defined as an interval of longer than 60 days.
For the variables used in this study, facility type was classified as comprehensive
community cancer program, community cancer program, academic research cancer
program, and integrated network cancer program. Patient demographic data included age
at diagnosis, gender, race/ethnicity, insurance status, travel distance to treatment facility,
and Charlson-Deyo comorbidity score, which is a comorbidity index based on ICD
diagnosis codes. Clinical data consisted of AJCC TNM stage, preoperative serum alphafetoprotein (AFP), size of primary tumor, tumor grade (collected at pathologic diagnosis),
Model for End-Stage Liver Disease (MELD) score, and surgical intervention of primary site
(LTD and resection). Treatment surgery was defined as cancer-directed surgical
intervention, excluding incisional biopsy. In the database, LTD included but was not limited
to RFA, electrocautery ablation, laser ablation, photodynamic therapy, cryosurgery,
percutaneous ethanol injection, and acetic acid injection. Partial or simple removal of the
primary tumor site, which consisted of wedge resection, segmental resection, lobectomy,
and extended lobectomy were considered as surgical resection.

Statistical analysis
All data analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC).
Descriptive statistics were performed on patient demographics and clinical characteristics.
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Chi-square test was utilized to examine the association of categorical variables, and
Mann-Whitney U nonparametric test reported mean and standard deviation for the
continuous variable. To identify factors associated with surgical delay, all demographic
and clinical factors with the exception of MELD score were first assessed in univariate
analysis. The candidate variables with statistical significance (inclusion P <0.10) were then
entered into a multivariate generalized linear mixed model accounting for clustering of
outcomes within hospitals. Patient survival was determined in months from the date of
diagnosis to the date of last contact or death as a result of any cause, and patients were
censored at the time of lost to follow-up. The 5-year unadjusted survival based on time
from diagnosis to surgery was examined using Kaplan-Meier plots stratified by surgical
intervention, and significance was evaluated by log-rank test. A Cox proportional hazards
frailty model adjusting for all factors (except for MELD score) was built to determine the
predictors of overall survival and adjusted risk ratios. Since components of the MELD
score were included in the database starting 2010, we were not able to adjust for this
variable in survival analysis due to insufficient years of follow-up. In addition to using 60
days as the main cutoff point to define surgical delay, survival was further evaluated using
wait time cutoffs at 50, 70, 80, 90 and 100 days, adjusting for demographic and clinical
factors. For all tests, a two-tailed P value of less than 0.05 was considered statistically
significant.
As the NCDB is a de-identified database, this study was exempted from review by
the University of Nebraska Medical Center Institutional Review Board.

Results
Patient demographics
The median follow-up time of the entire cohort was 25.9 months (range: 0–130.0
months), and median wait time from diagnosis to definitive surgery was 50 days
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(interquartile range: 29–86 days). Figure 4 illustrates the distribution of wait time to
surgery by month-intervals. A total of 4,987 patients (41.2%) had a wait time >60 days
after date of HCC diagnosis. Within the delayed group, 85 patients (1.7%) underwent
surgery after a year since diagnosis. Among all patients, 52.5% underwent LTD and 47.5%
received resection. The mean age of diagnosis was 62.5 years and most patients were
male (72.5%). Based on patient demographic characteristics (Table 10), delayed patents
were more likely be male (74.5% vs. 71.1%), African American race (16.2% vs. 13.1%),
Medicaid holder (16.6% vs. 12.3%), and traveling for >100 miles to treatment facilities
(12.3% vs. 10.6%). There was also a greater proportion of delayed patients treated in
academic research cancer centers (71.5% vs. 66.5%). In terms of clinical characteristics,
there was a greater proportion of non-delayed patients who had stage III disease (18.6%
vs. 13.9%), with primary tumor >5 cm (36.3% vs. 25.5%), and having poorly
differentiated/undifferentiated tumor (14.9% vs. 9.2%). Furthermore, in comparison,
delayed patients tended to have underwent surgical resection (53.8% vs. 38.7%).

Independent factors associated with surgical delay
Table 11 outlines the results from multivariate analysis, and presents the
demographic and clinical factors that were significantly associated with wait time to
surgery. As shown, travel distance to treatment facility of >100 miles versus ≤10 miles
increased odds of delay by 25% (OR: 1.25; 95% CI: 1.08–1.46). Female patients had a
lower odds for experiencing delay (OR: 0.85; 95% CI: 0.78–0.94), and African Americans
had a higher odds for having delayed surgery compared to non-Hispanic Caucasian
patients (OR: 1.32; 95% CI: 1.17–1.49). Likewise, the odds for delay was higher among
Medicaid beneficiaries compared to private insurance holders (OR: 1.28; 95% CI: 1.13–
1.45). Clinically, patients with poorly differentiated or undifferentiated tumor had a lower
odds for delayed surgery compared to those with well differentiated tumor (OR: 0.70; 95%
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CI: 0.60–0.83), and this was also the trend for larger tumor versus tumor <2 cm (2-5 cm
vs. <2 cm [OR: 0.87; 95% CI: 0.77–0.99]; >5 cm vs. <2 cm [OR: 0.70; 95% CI: 0.60–0.81]).
Moreover, Compared to LTD intervention, patients treated with resection were less likely
to experience delay (OR: 0.70; 95% CI: 0.63–0.78).

Estimates of survival probability
In this cohort, the median survival was 37.7 months for delayed patients and 36.6
months in patients without surgical delay. Figure 5 presents the Kaplan-Meier estimates
of wait time to surgery, and Figure 6 details the unadjusted stage-specific survival
probability. For all stages combined, compared to patients without delay, delayed patients
had significantly better 5-year survival for LTD (29.1% vs. 27.6%; P =.001) and resection
(44.1% vs. 41.0%; P <.001). Likewise, this trend was correspondingly observed for 3-year
survival (delayed vs. non-delayed: LTD [45.1% vs. 42.8%]; resection [61.8% vs. 56.7%]),
and 1-year survival (delayed vs. non-delayed: LTD [82.7% vs. 74.8%]; resection [85.4%
vs. 80.1%]). For stage-specific 5-year survival, more favorable prognosis was observed in
delayed patients who underwent LTD for stage II (28.7% vs. 23.6%; P =.008) and stage
III disease (11.9% vs. 11.4%; P =.003), and surgical resection for stage III disease (27.2%
vs. 22.0%; P =.002). In sum, no comparison revealed a significantly higher survival
probability among patients without delay.

Independent factors associated with risk-adjusted overall survival
As indicated in Table 12, patients who received surgery >60 days after diagnosis
date had a 7% decreased risk of death than patients with wait time ≤60 days (HR: 0.93;
95% CI: 0.87–0.99; P =.027). Compared to cases treated in comprehensive community
cancer programs, those who received care in academic research cancer programs had a
14% decreased risk of mortality (HR: 0.86; 95% CI: 0.79–0.94). Of the demographic
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factors, Asian race was a predictor of decreased mortality risk (HR: 0.76; 95% CI: 0.68–
0.84). Significant prognostic factors for worse survival consisted of Medicaid (HR: 1.12;
95% CI: 1.00–1.24) and Medicare insurance coverage (HR: 1.12; 95% CI: 1.03–1.22),
Charlson-Deyo score ≥2 (HR: 1.19; 95% CI: 1.09–1.29), stage II (HR: 1.11; 95% CI: 1.03–
1.20) and stage III disease (HR: 1.51; 95% CI: 1.37–1.67), elevated AFP level (>500 ng/ml)
(HR: 1.23; 95% CI: 1.15–1.33), and primary tumor >5 cm (HR: 1.24; 95% CI: 1.09–1.40).
Compared to LTD, surgical resection was associated with a 27% decreased risk of death
(HR: 0.73; 95% CI: 0.67–0.80).

Overall survival using other wait time cutoffs
As shown in Table 13, wait time to surgery was dichotomized in a range of cutoff
points from 50 to 100 days. In risk-adjusted overall survival, delayed patients consistently
presented improved outcomes. Patients with a wait time longer than 50 days (HR: 0.93;
95% CI: 0.87–0.99), 70 days (HR: 0.91; 95% CI: 0.85–0.97), 80 days (HR: 0.93; 95% CI:
0.86–0.99), 90 days (HR: 0.91; 95% CI: 0.84–0.98), and 100 days (HR: 0.92; 95% CI:
0.84–0.99) all demonstrated decreased risk of death compared to those without delayed
surgery.

Discussion
To our knowledge, this is the first study utilizing large-scale data to investigate the
association of surgical delay and HCC outcomes, as well as the factors associated with
wait time to surgery. As the NCDB is a national database that consists of hospital registry
data collected from commission-accredited cancer programs across the United States,
findings generated from this study should be more generalizable than results obtained
from studies of single centers. Although it is often assumed that delay in surgery has a
harmful impact on cancer prognosis, we observed that delay was associated with more
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optimal outcomes. This finding was consistently observed in unadjusted 5-year survival,
as well as in covariates-adjusted overall survival based on wait time intervals ranging from
50 to 100 days. With the exception of a study conducted by Akce et al. [19], which found
delay to be associated with decreased risk of death among patients from the Department
of Veterans Affairs treated with curative surgery, liver-directed therapy, or chemotherapy
for BCLC stage C HCC (HR: 0.50; 95% CI: 0.37–0.67), other studies of hepatocellular
carcinoma patients have reported that either prolonged wait time to surgery was linked
with shortened survival [13-17] or that no significant association was observed [18]. In
contrast to the majority of existing studies utilizing medical records, this retrospective
analysis that is based on large comprehensive clinical data provides a different
perspective.
While findings of this study are counterintuitive, previous research that investigated
the impact of delays in diagnosis-to-treatment, first hospital visit-to-treatment, and general
practitioner referral-to-treatment in lung [143-145], colon [146], endometrial [147], and
bladder [148] cancers also found similar trends in which prolonged wait time to surgery
was associated with more optimal outcomes. A plausible explanation of this phenomenon
is that tumor aggressiveness may influence delay, with more severe and advanced cases
being referred to have more urgent treatments. This is also known as the waiting-time
paradox, which is caused by the inclusion of patients with more severe conditions who
invariably present early and have poor outcomes due to disease advancement [140]. In
other words, the disease itself, such as its aggressiveness may have an influence on
treatment delay; thus, delay could be a confounding factor [147]. A study that comprised
769 patients surgically treated for colon cancer found that for every quartile increase in
delay, odds of mortality decreased by a ratio of 0.78 [146]. The authors speculated that
the advanced and high-risk cases were referred for workup and scheduled to be operated
on sooner; therefore with prioritization, delay did not pose substantial risk of worsening
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prognosis [146]. Furthermore, studies conducted in lung cancer patients suggested that
cases with severe signs and higher symptom burden are likely to receive prompt treatment,
while candidate patients of curative treatments might have to wait longer [143-145]. As a
plausible explanation for our finding, the triage effect of operating on less urgent patients
at a later time may have led to reasonable delays as a result of completing more
comprehensive preoperative evaluation and staging for patients with less aggressive
tumors. In our analysis, we observed that patients with primary tumor ≥2 cm and of poorly
differentiated or undifferentiated grade (i.e. tumor biology) were significantly less likely to
experience delay. Thus comparatively, patients with less aggressive tumor biology were
treated at later times. These observations support our speculation about the practice of
case prioritization.
For comparison of 5-year survival between delayed versus non-delayed patients
(Figure 6), the strength of association or difference in survival probability increased in
advanced disease stage. For instance, among stage I patients who underwent resection,
the difference in 5-year survival probability between the two wait time groups was only
0.9% (53.5 subtract 52.6); however, stage III patients presented a survival difference of
5.2% (27.2 subtract 22.0). A similar trend was also observed in patients treated with LTD,
in which significant association was observed in stage III patients but not those with stage
I disease. Likewise, Akce and colleagues demonstrated that delay was associated with
decreased risk of mortality in HCC patients with BCLC stage C, but no association was
detected for BCLC stage 0 and A or BCLC stage B [19]. These results further confirm our
speculation about the practice of prioritizing more serious cases in advanced stage.
Furthermore, our descriptive result indicated that 71.5% of delayed patients were treated
in academic research cancer programs, while this number was lower for non-delayed
patients (66.5%). In this cohort, patients who were treated in academic cancer centers
had the most favorable outcome. Since academic hospitals are more suited to manage
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the complicated and multi-disciplinary care that HCC surgeries often require [149],
patients with less urgent conditions who were treated at a later time likely received more
comprehensive preoperative assessment and postoperative follow-up offered in academic
research cancer centers.
Another explanation for our finding is that this study examined survival starting
from diagnosis rather than from the onset of symptoms. It is known that an assessment
that begins from an earlier time point would likely avoid lead-time-bias, and the increase
in survival could be due to earlier diagnosis. In covariates-adjusted analysis, we were not
able to account for certain potential confounding factors, including liver disease etiology,
clinical indications of liver dysfunction (such as presence of hepatic encephalopathy and
ascites), and laboratory values/scores (such as liver enzymes and Child-Turcotte-Pugh
score) due to unavailability or largely missing values. Although risk-adjusted analyses
included disease stage and tumor grade, stage is based on structural involvement and
grade is determined by pathological appearance; these factors were not able to fully
characterize direct liver function.
Currently, there is scarce research using covariates-adjusted analysis to
investigate the predictors of delay in HCC surgery (Table 11). Consistent with our finding,
a study using records abstracted from the Pennsylvania Cancer Registry found that HCC
patients who underwent resection, lobectomy or partial hepatectomy were 52% less likely
than patients treated with locoregional intervention to experience surgical delay [142]. In
addition, the same study reported that male gender was a predictor of delay [142].
Corresponding to our results, a study that utilized the 1995-2005 NCDB file consisting of
1,228,071 patients who underwent resection for gastrointestinal and breast cancers
observed that African American race and Medicaid insurance were demographic factors
significantly associated with prolonged wait time to treatment [150]. Similar to our finding,
previous studies have shown that longer travel distance to facility was a predictor of
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surgical delay in patients treated for cancers of the pancreas [151] and bladder [152]. We
also found that cases with a primary tumor 2 cm or larger were less likely to experience
delay. An explanation for this is that in comparison, resection resulted in a 30% decreased
odds of delay, and 93.7% of resection procedures were performed on primary tumor ≥2
versus 80.9% for LTD. Additionally, we observed that patients without delay were more
likely to be treated in centers that did not perform liver transplantation; as 30.1% of nondelayed patients were treated in non-transplant programs compared to 25.8% of delayed
patients. This likely suggests that a number of patients underwent prompt surgery due to
that transplant program was not available in where they received care.
There are several limitations in this study that should be noted. First, due to the
retrospective nature of this database, information concerning to patient and physician
treatment decision-making cannot be captured in detail. As a result, we could not assess
the case prioritization approach in HCC surgical care, and its level of impact on our
findings. As discussed previously, we were unable to examine certain clinical preoperative
indications of liver dysfunction (presence of hepatic encephalopathy and hepatic ascites),
and preoperative laboratory values/scores (liver enzymes and Child-Turcotte-Pugh score).
Although data from which MELD score can be calculated are available (international
normalized ratio of prothrombin time, bilirubin, and creatinine), this information is largely
missing (67.3%) due to unavailability until 2010. Furthermore, since chemoembolization
was coded as chemotherapy in the database, we were unable to distinguish between
transarterial therapy and systemic chemotherapy; thus, we did not include chemotherapy
in risk-adjusted analyses. In this cohort, survival analysis was based on all-cause death
rather than HCC-specific death as cancer-specific survival data were not captured. These
limitations should serve to call for an improvement in the quality of NCDB data and to
include additional clinically relevant variables. Nevertheless, taking all factors into
consideration, we believe that the strengths of this study outweigh its limitations.
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To summarize, this analysis using NCDB data found that delay in HCC surgical
treatment was associated with decreased risk of death, and this phenomenon was
observed in patients who underwent LTD and resection. These findings should not be
perceived as an encouragement to delay time to surgery or prolong wait time. Rather, the
results suggest that a reasonable delay in surgery that is potentially based on tumor
aggressiveness and severity does not appear to put patients at increased risk of death.
Further studies are strongly warranted to understand and re-evaluate the advantages
associated with undergoing early surgery for HCC. Additionally, it would be of significance
to explore the impact of symptom-to-treatment delay or diagnostic delay on HCC
outcomes.
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Figure 3. Diagram for patient selection. Abbreviations: NCDB, National Cancer Database;
LTD, local tumor destruction.

Primary hepatocellular carcinoma
(8180-8175) in NCDB 2004-2013
(n=118,800)

Excluded:
Cases not treated with LTD or surgical resection (n=97,253)
Stage IV disease (n=545)
Unknown stage (n=2,601)
Sequence number other than “00” or “01” (n=2,776)
Underwent cancer directed surgery prior to definitive surgery
(n=342)
Unknown wait time, or date of diagnosis was the same as date
of definitive surgery (n=3,172)
Underwent definitive surgery past 2 years after diagnosis (n=9)

Final analytic cohort
(n=12,102)
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Figure 4. Patient distribution of wait time from diagnosis to surgery by month-intervals.
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Table 10. Demographic and clinical characteristics based on wait time from diagnosis to
surgery.
Wait Time to Surgery
Characteristics

Facility classification
Comprehensive community cancer program
Community cancer program
Academic research cancer program
Integrated network cancer program
Unknown/other
Age at diagnosis
Gender
Male
Female
Race/ethnicity
Non-Hispanic Caucasian
Black
Asian
Hispanic
Unknown
Insurance status
Private
Medicaid
Medicare
Not insured
Unknown
Travel distance to facility
≤10 miles
10.1-50 miles
50.1-100 miles
>100 miles
Unknown
Charlson-Deyo comorbidity score
0
1
≥2
AJCC TNM stage
I
II
III
Alpha-fetoprotein level
Normal
Elevated
Unknown

≤60 days
(n=7115) n (%)

>60 days
(n=4987) n
(%)

P
Value

<.001
1487 (20.9)
192 (2.7)
4730 (66.5)
468 (6.6)
238 (3.4)
62.8 ± 11.8

916 (18.4)
114 (2.3)
3563 (71.5)
318 (6.4)
76 (1.5)
62.0 ± 10.3

<.001
<.001

5055 (71.1)
2060 (29.0)

3716 (74.5)
1271 (25.5)

4266 (60.0)
933 (13.1)
873 (12.3)
670 (9.4)
373 (5.2)

2793 (56.0)
810 (16.2)
564 (11.3)
587 (11.8)
233 (4.7)

2621 (36.8)
873 (12.3)
3159 (44.4)
266 (3.7)
196 (2.8)

1726 (34.6)
829 (16.6)
2098 (42.1)
197 (4.0)
137 (2.8)

2791 (39.2)
2626 (36.9)
819 (11.5)
754 (10.6)
125 (1.8)

1971 (39.5)
1731 (34.7)
593 (11.9)
613 (12.3)
79 (1.6)

3486 (49.0)
2070 (29.1)
1559 (21.9)

2352 (47.2)
1434 (28.8)
1201 (24.1)

<.001

<.001

.015

.016

<.001
3980 (55.9)
1811 (25.5)
1324 (18.6)

2893 (58.0)
1401 (28.1)
693 (13.9)

1814 (25.5)
3446 (48.4)
1855 (26.1)

1313 (26.3)
2628 (52.7)
1046 (21.0)

<.001
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Tumor size
<2 cm
2-5 cm
>5 cm
Unknown
Tumor grade
Well differentiated
Moderately differentiated
Poorly differentiated/undifferentiated
Unknown
MELD score
Surgical intervention of primary site
Local tumor destruction
Surgical resection

<.001
780 (11.0)
3485 (49.0)
2584 (36.3)
266 (3.7)

724 (14.5)
2832 (56.8)
1269 (25.5)
162 (3.3)

1241 (17.4)
2198 (30.9)
1063 (14.9)
2613 (36.7)
13.0 ± 8.6

902 (18.1)
1268 (25.4)
461 (9.2)
2356 (47.2)
13.1 ± 8.5

3291 (46.3)
3824 (53.8)

3057 (61.3)
1930 (38.7)

<.001

.75
<.001
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Table 11. Generalized linear mixed model to evaluate factors associated with wait time to
surgery.
Wait Time to Surgery
>60 days versus ≤60 days
Characteristics
Facility classification
Comprehensive community cancer program
Community cancer program
Academic research cancer program
Integrated network cancer program
Age at diagnosis
Gender
Male
Female
Race/ethnicity
Non-Hispanic Caucasian
Black
Asian
Hispanic
Insurance status
Private
Medicaid
Medicare
Not insured
Travel distance to facility
≤10 miles
10.1-50 miles
50.1-100 miles
>100 miles
Charlson-Deyo comorbidity score
0
1
≥2
AJCC TNM stage
I
II
III
Tumor size
<2 cm
2-5 cm
>5 cm
Tumor grade*
Well differentiated
Moderately differentiated
Poorly differentiated/undifferentiated

Adjusted
Odds Ratio

95% CI

P
Value

Reference
0.94
1.06
0.89
0.99

0.70–1.25
0.79–1.40
0.62–1.29
0.99–1.00

.65
.71
.53
.017

Reference
0.85

0.78–0.94

<.001

Reference
1.32
1.05
1.12

1.17–1.49
0.92–1.21
0.97–1.29

<.001
.46
.11

Reference
1.28
1.07
1.04

1.13–1.45
0.96–1.19
0.83–1.31

<.001
.21
.71

Reference
1.00
1.03
1.25

0.91–1.10
0.89–1.19
1.08–1.46

.99
.72
.004

Reference
0.93
0.97

0.85–1.03
0.87–1.08

.17
.56

Reference
1.07
0.97

0.97–1.18
0.85–1.11

.18
.67

Reference
0.87
0.70

0.77–0.99
0.60–0.81

.032
<.001

Reference
0.90
0.70

0.80–1.02
0.60–0.83

.11
<.001

93
Unknown
Surgical intervention of primary site
Local tumor destruction
Surgical resection

1.00

0.88–1.13

.98

Reference
0.70

0.63–0.78

<.001

Alpha-fetoprotein level was not included due to insignificance in univariate analysis.
*Missing values (41.1%) for tumor grade were grouped into “Unknown” category.

94
Figure 5. Kaplan-Meier survival estimates of wait time to surgery: A). Local tumor
destruction (N=5254); B). Surgical resection (N=4996).

A).

B).
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Figure 6. Survival probability of 1-year, 3-year, and 5-year, stratified by wait time, surgical
intervention, and disease stage: A). Local tumor destruction; B). Surgical resection.

A).
100.0

Survival Probability

80.0

60.0

P =.45
40.0

P =.008

P =.001

P =.003
20.0

0.0

Stage Stage Stage
Total
I
II
III
1-Year Survival
Non-delay 81.0 73.7 50.4 74.8
Delayed
86.4 82.2 64.4 82.7

Stage Stage Stage
Total
I
II
III
3-Year Survival
50.0 39.5 19.2 42.8
50.9 41.9 23.7 45.1

Stage Stage Stage
Total
I
II
III
5-Year Survival
33.3 23.6 11.4 27.6
32.6 28.7 11.9 29.1

B).
100.0

80.0

Survival Probability

P =.24
60.0

P =.27

P <.001

P =.002

40.0

20.0

0.0

Stage Stage Stage
Total
I
II
III
1-Year Survival
Non-delay 87.5 79.0 66.1 80.1
Delayed
89.2 83.1 78.4 85.4

Stage Stage Stage
Total
I
II
III
3-Year Survival
68.3 54.0 36.0 56.7
71.3 57.5 43.1 61.8

Stage Stage Stage
Total
I
II
III
5-Year Survival
52.6 37.6 22.0 41.0
53.5 39.2 27.2 44.1
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Table 12. Cox proportional hazards frailty model to estimate adjusted-risk of overall
mortality.

Characteristics
Wait time to surgery
Wait time ≤60 days
Wait time >60 days
Facility classification
Comprehensive community cancer program
Community cancer program
Academic research cancer program
Integrated network cancer program
Age at diagnosis
Gender
Male
Female
Race/ethnicity
Non-Hispanic Caucasian
Black
Asian
Hispanic
Insurance status
Private
Medicaid
Medicare
Not insured
Travel distance to facility
≤10 miles
10.1-50 miles
50.1-100 miles
>100 miles
Charlson-Deyo comorbidity score
0
1
≥2
AJCC TNM stage
I
II
III
Alpha-fetoprotein level
Normal
Elevated
Tumor size
<2 cm
2-5 cm
>5 cm

Adjusted HR

95% CI

P
Value

Reference
0.93

0.87–0.99

.027

Reference
1.04
0.86
1.05
1.01

0.83–1.30
0.79–0.94
0.91–1.21
1.00–1.01

.76
<.001
.51
<.001

Reference
0.95

0.88–1.02

.14

Reference
1.05
0.76
1.01

0.95–1.15
0.68–0.84
0.90–1.12

.38
<.001
.93

Reference
1.12
1.12
1.04

1.00–1.24
1.03–1.22
0.85–1.26

.042
.009
.71

Reference
0.92
1.03
1.03

0.85–0.99
0.92–1.15
0.92–1.16

.029
.60
.61

Reference
0.99
1.19

0.92–1.07
1.09–1.29

.85
<.001

Reference
1.11
1.51

1.03–1.20
1.37–1.67

.008
<.001

Reference
1.23

1.15–1.33

<.001

Reference
1.03
1.24

0.93–1.14
1.09–1.40

.61
<.001
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Tumor grade*
Well differentiated
Moderately differentiated
Poorly differentiated/undifferentiated
Unknown
Surgical intervention of primary site
Local tumor destruction
Surgical resection

Reference
0.97
1.08
1.07

0.88–1.07
0.95–1.23
0.97–1.18

.53
.22
.19

Reference
0.73

0.67–0.80

<.001

*Missing values (41.1%) for tumor grade were grouped into “Unknown” category.

Table 13. Adjusted-risk of overall mortality based on wait time cutoffs range from 50 to
100 days, using 10-day increment.

Wait Time to Surgery

% Patients
with Delay

Adjusted HR

95% CI

P Value

>50 days
>60 days
>70 days
>80 days
>90 days
>100 days

49.8
41.2
33.7
27.8
23.3
19.5

0.93
0.93
0.91
0.93
0.91
0.92

0.87–0.99
0.87–0.99
0.85–0.97
0.86–0.99
0.84–0.98
0.84–0.99

.035
.027
.007
.048
.018
.040

Each comparison was referenced to the non-delayed group.
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CHAPTER V
DISCUSSION AND CONCLUSIONS

Summary of current research
According to the Global Burden of Disease 2015 study, there were 854,000
incident cases and 810,000 deaths of liver cancer, which contributed to a total of
20,578,000 disability-adjusted life-years [1]. Furthermore, primary liver cancer incidence
increased by 75% between 1990 and 2015, and liver cancer is a major public health
burden globally [1]. China, of all countries, has been most affected by liver cancer. In
China, the biggest risk factor for developing HCC is chronic infection with viral hepatitis,
particularly HBV. The disease burden of HBV is the highest among communicable
diseases, and about 10 million Chinese living with chronic HBV are expected to die by
2030, with a significant proportion due to HCC [153]. As the risk of developing HCC is
significantly greater among patients with chronic hepatitis [36], HCC incidence could be
reduced with the practice of recommended bi-annual cancer screening and antiviral
therapy treatment. Among high-risk patients with chronic viral hepatitis, undergoing
screening has shown to improve the rates for early HCC detection and eligibility for
receiving curative treatments, and antiviral therapy plays a critical role in delaying liver
disease progression and decreasing the likelihood of developing HCC.
Aim 1 of this dissertation investigated the practice, knowledge and self-perceived
barriers to undertaking HCC surveillance among 352 patients with chronic HBV and/or
HCV infection, and reported that only 50.0% of patients had routine bi-annual screening
with ultrasound and AFP. Aim 2 examined the adherence rates and perceived barriers to
NUC antiviral therapy among 369 patients chronically infected with HBV, and observed
that over half (51.2%) of the subjects were measured with low adherence while a
significantly smaller proportion had high adherence (16.5%). For both studies, a number
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of socio-demographics and clinical factors were analyzed in multivariable regression
analyses to evaluate the association of these factors with our outcomes of interest, and
we found that rural residency was a significant predictor on patients’ HCC knowledge and
antiviral medication adherence. Results from Aim 1 indicated that patients of rural regions
had knowledge scores (based on questions about viral hepatitis transmission, and liver
cancer prevention, progression and screening guidelines) that were 1.25 points lower than
patients living in urban areas (P =0.002). In Aim 2, we found that patients residing in urban
regions were 4.88 times more likely to have high medication adherence as opposed to low
adherence compared to patients from rural regions. Over the past decade, China has
experienced a major rise in economic development; however, there are serious issues in
the health sector development with major gaps in urban and rural settings in areas of
health services allocation, utilization and health outcomes [123]. HCC has been reported
to have higher incidence and mortality rates in rural areas of China, which are likely
contributed by the lack of medical resources and poor quality of medical services [154,
155]. Moreover, there are lack of oncologists working in the rural regions, as hospitals
located in rural regions are having a hard time retaining qualified oncologists [156].
In addition to difficulty in accessing quality healthcare, chronic viral hepatitis has
been considered as an economically disastrous disease in China, and costs are especially
burdensome among individuals living in rural regions. It is estimated that less than 5% of
rural patients are able to afford treatment for at least one year, as compared to 40% of
those living in developed areas [123]. As a result, many rural patients infected with chronic
hepatitis are unable to receive timely and quality treatment, and this is another reason
rural HCC patients have a higher mortality. Our findings suggest that there is an urgency
to implement more effective interventional measures to better educate patients residing in
rural China, and to make healthcare more accessible and affordable. These
recommended interventions include implementing more equitable access to clinical and
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pharmaceutical services in rural and remote areas, increasing reimbursement for
pharmaceutical treatments to reduce the barriers in medication affordability, urging the
government to enter into negotiations with the generic drug manufacturers of entecavir to
provide less costly drugs, urging the government to accelerate its public investment into
public health system, and organizing mass public awareness campaigns to increase
knowledge about management of chronic hepatitis and HCC preventive strategies [123].
Using structured questionnaires to evaluate patients’ self-identified barriers, we
found that the most commonly reported barriers were closely associated with an
inadequate knowledge and poor health awareness. For instance, 41.5% of participants
from Aim 1 reported that they did not know screening for HCC existed, 38.3% stated that
there is no need for screening because of no symptom or physical discomfort, and 45.1%
of patients from Aim 2 cited forgetfulness as the reason for skipping NUC medications.
These results further show that health education in liver cancer prevention is critical to
enhance compliance to HCC surveillance and antiviral treatment. There is also the need
to provide accessible and accurate information to the high-risk patients. Healthcare
providers should work closely with community health leaders to better inform high-risk
patients about diseases associated with chronic viral hepatitis, as well as clinical
management access, prevention and control measures, and recommended lifestyles [123].
Patients should fully understand that HBV and HCV are major risk factors for developing
HCC and other serious adverse conditions of the liver, and that these health conditions
require regular monitoring and the appropriate treatment for viral suppression.
Although antiviral medications are available to slow down disease progression in
patients with chronic viral hepatitis, a number of these patients will eventually develop
HCC. Due to the poor prognosis of HCC, curative treatments such as RFA, surgical
resection and transplantation are usually only offered in the early-stage, indicating that
early active treatment is critical to increase the chance of survival. However, based on
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findings from Aim 3, we found that surgical delay in LTD and hepatic resection was
associated with a more favorable 5-year survival and risk-adjusted long-term overall
survival. Using a range of cutoff values to define surgical delay, including 50, 60, 70, 80,
90 and 100 days, all cutoffs demonstrated that prolonged wait time from diagnosis to
surgery was significantly correlated with a decreased risk of death.
These findings we obtained do not align with our initial hypothesis that a longer
wait time to surgery would adversely affect prognostic outcomes. This hypothesis was
developed based on previously published literature conducted in HCC patients who
underwent loco-regional therapies, hepatic resection, and other HCC-directed treatments
[13-19]. Previous studies found that delay from diagnosis to surgery was associated with
shortened survival and an increased risk of mortality [13-19]. We also developed this
hypothesis because it is known that early HCC detection would improve the patients’
chance to receiving curative surgeries [138]. Unfortunately, it is difficult to make direct
comparison of our findings with those of previously published literature due to major
differences in the data sources used. We utilized a large national comprehensive oncology
database as opposed to medical records from single treatment centers, and while previous
studies included a number of clinically relevant values in their analyses (i.e. disease
etiology, liver dysfunction indicators, liver enzymes), our risk-adjusted models were
generated with the absence of such variables due to unavailability. This limitation was
recognized, but could not be overcome.
It is important to note that a number of similar studies conducted in lung [143-145],
colon [146], endometrial [147], and bladder [148] cancers have also produced
counterintuitive results, and suggested these findings are likely attributed to the waitingtime paradox, in which patients with more severe and advanced conditions are being
referred for prompt treatment. These patients who are being operated on early are more
likely to have poor outcomes due to disease advancement, while patients with less

102
aggressive tumors are being treated later and receive more comprehensive preoperative
evaluation and clearance. As a result of the prioritization approach, surgical delay did not
appear to have a harmful impact on survival because this triage selection process
produced two treatment groups of patients (non-delay vs. delayed) with different clinical
conditions. This phenomenon is also evident by our findings in which patients with primary
tumor larger than 2 cm, poorly differentiated or undifferentiated grade, and advanced
disease stage were less likely to experience surgical delay. Given the results obtained,
HCC surgical care prioritization seems to be a reasonable approach, as a prolonged wait
time to surgery that is likely based on tumor aggressiveness and advancement did not
increase patients’ risk of death.

Limitations
This dissertation consists of both primary survey data collected among Chinese
hospital patients and a national hospital-based oncology registry data. There are several
limitations associated with the collection and use of primary data in aims 1 and 2. A major
limitation is that electronic medical record (EMR) systems are not currently wellestablished in the vast majority of medical institutions in China. As our studies were
conducted in two tertiary hospitals in Shanghai and Wuhan, the collected survey data were
based on patients’ self-report and formal verification for data accuracy could not be
performed. To improve the quality of epidemiologic and clinical research in China, it is of
importance for China to establish and widely implement the EMR system. This universal
system of EMR should be the same across the entire country, and should be accessible
to any medical institution and health clinic, while still providing privacy and security of
patient information.
Furthermore, these studies were conducted among Chinese hospital patients in
major tertiary hospital of large urban cities, Shanghai and Wuhan, with population sizes
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comparable to New York City and Chicago, respectively. We were not able to fully capture
the knowledge level, attitudes and self-identified barriers for cancer screening and
medication treatment among patients from rural regions. Since major gaps in healthcare
disparities, economic development, and cultural customs exist between urban and rural
regions in China, findings generated from these studies are subject to geographical
limitations. Another limitation is that because we used convenience sampling method,
there is the possibility that sampling bias was introduced and this may limit the external
validity of the studies’ results. In comparison to population-based probability sampling,
convenience sampling produces estimates that are more generalizable to the sample
studied, whereas results produced from population based sampling could yield more
representative estimates of the target population. Additionally, our patient recruitment
design is subject to potential selection bias. The reason is that patients who visit
healthcare facilities tend to have better health awareness and are therefore more likely to
stick with disease management plans.
For Aim 3, the biggest limitation is that the NCDB does not have information on a
number of preoperative clinically relevant factors, including liver dysfunction (i.e. hepatic
encephalopathy, ascites) and laboratory values (i.e. MELD score, liver enzymes, ChildTurcotte-Pugh score). As a result, we were not able to adjust for these potential
confounding factors, which could have had an impact on our findings. Often times, cancer
registry databases do not provide information on cancer recurrence, and the NCDB is no
exception. We were not able to evaluate recurrence-free survival or the impact of surgical
delay on HCC recurrence. Furthermore, because chemoembolization was coded as
chemotherapy, we were unable to determine whether a number of patients underwent
trans-arterial therapy or systemic chemotherapy treatment. Lastly, without available
information on patient and physician treatment decision-making, we can only speculate
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that the counterintuitive findings were attributed to surgical prioritization based on tumor
severity and advancement, but no definitive conclusion can be made.

Future directions
Future research that aims to evaluate HCC screening practice or antiviral
medication adherence in high-risk patients should consider to recruit participants from
community-based settings. In the past, there was no well-established primary care system
in China, but in recent years, China has put substantial emphasis into primary care [157,
158]. This enables routine blood screening of the general population, making early
diagnosis of HBV and HCV possible. One method for identifying infected individuals in
local communities and acquire their contact information is to work with primary care
physicians, who should have a list of individuals tested positive for HBV or HCV infection
through annual blood exams. Given the approval for data usage and necessary patient
consent, researchers would be able to recruit study subjects in community settings
through telephone interviews and potentially door-to-door visits (note that Chinese
populations do not respond well to mailed brochures). This recruitment process would
likely yield a more representative sampling, as it would allow investigators to collect
information from many high-risk patients who do not visit hospitals or are not receiving the
appropriate specialty care (which can be due to low health awareness, indifference about
disease condition, and avoiding medical care costs). Additionally, similar studies can be
conducted in endemic regions, as a number of regions in China are considered as high
endemic areas for developing HCC. For instance, the city of Qidong, which is located in
the north shore of the Yangtze River, is known to have the highest population-based
incidence of liver cancer across China and in the world [159].
Furthermore, future studies should focus on Chinese patients residing in rural and
impoverished regions. Based on our findings, urban patients were more likely to have high
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medication adherence and were more compliant with undergoing HCC screening
compared to residents of rural regions. Since rural patients represented just 19.2% and
14.2% of our samples for aims 1 and 2, respectively, we were not able to evaluate the
research objectives solely using rural patients due to insufficient samples. In China,
disparities in social and economic development, as well as healthcare quality exist in the
urban and rural regions. These include but are not limited to income and education level,
healthcare accessibility and utilization, qualifications of local healthcare providers, medical
resources at treatment facilities, and health insurance coverage. Thus far, no published
studies has focused to evaluate the practice, knowledge level, and perceived barriers for
liver cancer prevention and control among high-risk rural Chinese patients. As major
health disparities exist in different regions of China and rural patients are known to have
higher incidence and mortality rates for HCC [154, 155], it is of significance to assess the
practice of HCC prevention and surveillance in non-urban settings.
In terms of clinical implication, one potential strategy to improve HCC surveillance
in China is through the development and utilization of at-home screening kits, and there
is a need to conduct extensive research in this area. As known, the most important
mechanism for improving curative rates of HCC is to enhance early detection rates, as
patient survival largely depends on the disease stage [29]. However, current medical
technologies used in surveillance can be expensive for certain populations in China [160].
Due to financial restraints and depending on where patients receive care, not all high-risk
Chinese patients can have HCC screening covered through medical insurance [160]. The
other issue in undergoing routine surveillance is that there is limited number of healthcare
practitioners in China [154, 155]. This is especially the case in rural and impoverished
areas, where medical resources are scarce and there is lack of well-trained healthcare
providers [160]. One company has developed an at-home screening kit for detecting
colorectal cancer and advanced precancerous lesions through detecting tumor specific
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KRAS mutations, abnormal NDRG4, bone morphogenetic protein 3 methylation, and
hemoglobin immunoassays stool samples [161]. For at-home cervical cancer screening,
measures based on self-collected vaginal samples for HPV testing are available [162, 163].
Moreover, recently, highly sensitive nanoarray sensors for exhaled volatile organic
compounds have been created for the detection of lung cancer using breath samples [164,
165]. As of this date, at-home screening kit for HCC has not been developed, and there is
still a long way to go. Nevertheless, at-home screening tools would likely address the
aforementioned gaps in China, and would be worth the effort to conduct research in this
field to develop a kit with a satisfying sensitivity and specificity [160].
A meta-analysis consisting of 16 randomized clinical trials, published on JAMA
Internal Medicine, found that text message-based intervention roughly doubled the odds
of medical adherence in patients treated for various chronic diseases [161]. This increase
translated to an absolute increase of 17.8% (from 50% to 67.8%) [161]. Similarly, in Aim
2, we observed that patients who received regular reminders from family members were
3.13 times more likely to have high medication adherence. Since messaging can serve as
a useful tool for behavior change in disease prevention and monitoring, healthcare
providers should work with policy makers to consider in widely implementing and adopting
the use of automated computer programs in hospitals and clinics. This would allow daily
reminder messages to be sent to patients who are enrolled in the disease management
programs, and who are prescribed with life-term medications for treating chronic illnesses
(this would include patients treated for chronic hepatitis). An advantage of text messaging
over other interventions (such as patient education, counseling, allied health support) is
the ease of administration, in which a computerized program is built to generate messages
in an automated fashion [166].
Despite the availability of HBV antiviral therapy in China, the proportion of patients
who actually receive treatment is low, and the main barrier to treatment is the cost [132].
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Our findings should assist health policy makers to have a better understanding on the
magnitude of the economic burden of HBV-related illnesses in China. In addition, there is
the need for policy makers to design and implement strategic plans to allocate more
medical resources in rural and under-developed regions in China to improve chronic
hepatitis management, as well as developing plans that would allow rural patients who
seek care in urban hospitals to receive health insurance coverage. In China, compared to
urban residents, patients of rural regions are unable to receive the same healthcare
coverage and reimbursements when treated or cared in urban hospitals [167, 168]. This
is largely attributed by the household registration policy [167], in which residents are
classified as rural or urban based on their residential location [90]. Based on this
registration, rural residents are provided with the government-led insurance program
known as New Rural Cooperative Medical System [114], which usually has inferior
coverage and inconvenient reimbursement procedures compared to insurance programs
offered to urban residents [167]. The household registration policy was established to
control population migration and to determine eligibility for state-provided benefits [90].
For the next step, it would be of critical importance for policy makers to develop plans to
address this issue, so that rural patients residing in less resourceful areas could visit urban
hospitals to obtain higher quality of care and have it covered.
From using the NCDB database, we obtained counterintuitive findings and that our
results do not align with the majority of published literature. Thus, additional research is
strongly warranted to re-evaluate the relationship of prolonged surgical wait time and HCC
outcomes. Similar research should consider using the Surveillance, Epidemiology, and
End Results (SEER)-Medicare-Linked database. Different from the NCDB, which is
sourced from hospital registry data, the SEER-Medicare data reflect the linkage of two
large population-based data sources on cancer patients. SEER collects data on cancer
patient demographics, tumor site and morphology, stage at diagnosis, first course
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treatment, and survival follow-up from population-based cancer registries that cover 28%
of the U.S. population. A number of studies have utilized SEER-Medicare to investigate
the impact of treatment delay or surgical wait time on patient outcomes in melanoma,
breast and colon malignancies [169-171]. Although the NCDB has a strength in capturing
more cancer cases and contains treatment hospital characteristics, the major advantage
of SEER lies in its population-based sampling approach; whereas the NCDB collects data
from convenience sampling of hospitals accredited by the Commission on Cancer (CoC).
As a result, patient demographics within SEER data are more comparable to that of the
general U.S. population [172].
In order to better understand how the prioritization approach has an impact on
post-operative HCC survival, and to evaluate the level of impact prioritization has on
survival, future studies conducted prospectively in clinical settings are warranted. Given
that we used secondary data, we were unable to examine the patient and physician
treatment decision-making process, and were not able to determine why certain patients
had shorter or longer wait times. Although we found an association between surgical delay
and long-term HCC survival, no temporal relationship can be determined. The proposed
prospective studies should focus on assessing the decision-making process and identify
the factors or reasons that influence undergoing prompt or delayed HCC surgery.
Structured questionnaires can be provided to patients who are eligible for HCC-directed
surgeries and their treating physicians to assess treatment preferences, reasons for
treatment of choice, and concerns or barriers to receiving surgery. Additionally,
researchers should examine whether patients who undergo surgery at a later time have
comparatively better liver function, tumor biology, and less disease severity or
advancement. Lastly, patients should be followed prospectively for five years post-surgery
to compute for HCC-specific survival.
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As of this date, no study has explored the impact of symptom-to-treatment delay
or diagnostic delay on the prognosis of HCC. To evaluate the impact of treatment delay
from the onset of symptoms would likely serve to avoid lead time-bias. This would
eliminate the systematic error of an increased survival due to detecting disease at an
earlier stage. Moreover, examining symptom-to-treatment delay would also allow
researchers to better evaluate patient-level delay. Patient delay can be defined as time
from the patients’ first self-discovery of symptoms to time of clinic visit for medical
evaluation by a physician; whereas provider delay or health system delay is related to
delay in diagnosis and delay in the initiation of cancer treatment [173, 174].

Conclusions
Overall, this dissertation fills the gaps in knowledge about the adherence, attitudes,
and self-reported barriers to undertaking preventive HCC screening and NUC antiviral
therapy among the high-risk patients, as well as the association between surgical delay
and long-term prognosis among patients who have developed HCC. These findings could
assist healthcare providers and researchers to develop more effective educational
programs in China to improve patients’ awareness, knowledge level, attitudes, and
perceptions about HCC prevention and control; with an emphasis on viral hepatitis
management and undergoing timely HCC surveillance. These interventional programs
should also target patients residing in rural areas and with low socioeconomic status.
Moreover, there is a need for policy makers to step in, and to work collaboratively with
healthcare professionals to develop strategic plans that would make pharmaceutical care
more affordable in treating chronic hepatitis. Furthermore, our findings strongly call for the
adaptation of a universal EMR system across China to enhance epidemiologic and clinical
research. For treating patients with HCC, contrary to what is assumed, using a national
hospital-based cancer registry, our study added new evidence that delay in HCC surgery
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was associated with a decreased risk of mortality. This study calls for the use of other
large registry database to further explore the relationship of prolonged surgical wait time
and HCC prognosis, and indicates the need to conduct prospective studies to better
understand and validate the prioritization approach in HCC surgical care.
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APPENDIX A
Comparison of hepatocellular carcinoma surveillance guidelines published from
different professional organizations.
Organization
American Association for the Study
of Liver Diseases (AASLD) [36]

Date
published

Method

Interval

2018

Ultrasound,
with or without
AFP

Every 6
months

Cirrhotic patients, noncirrhotic
HBV carriers with a family
history of HCC, noncirrhotic
Africans and African
Americans with HBV,
noncirrhotic Asian male HBV
carriers past the age of 40
years, noncirrhotic Asian
female HBV carriers past the
age of 50 years.

2018

Ultrasound

Every 6
months

Cirrhotic patients, noncirrhotic
HBV carriers with a family
history of HCC, noncirrhotic
HBV carriers with active
hepatitis, noncirrhotic patients
with chronic HCV and
advanced liver fibrosis (F3).

2017

Combination
of AFP and
ultrasound

Every 6
months

Cirrhotic patients with HBV or
HCV infection, chronic HBV
carriers

2017

Ultrasound

Every 6
months

Cirrhotic patients, noncirrhotic
HBV carriers

2018

Combination
of AFP and
ultrasound

Every 6
months

Cirrhotic patients, noncirrhotic
HBV or HCV carriers, patients
with a family history of HCC

Link:
https://aasldpubs.onlinelibrary.wiley.
com/doi/abs/10.1002/hep.29913

European Association for the Study
of Liver (EASL) [175]
Link:
https://www.journal-ofhepatology.eu/article/S01688278(18)30215-0/fulltext
Asian Pacific Association for the
Study of Liver (APASL) [30]

Target population

Link:
http://www.clubepatologiospedalieri.it
/wp-content/uploads/2018/02/MOmata-APASL-Guidelines-HCC2017-Hep-Int.pdf
National Comprehensive Cancer
Network (NCCN) [176]
Link:
http://www.lidebiotech.com/nccn/20.p
df
National Health and Family Planning
Commission of the People’s
Republic of China [177]
Link:
https://www.karger.com/Article/FullT
ext/488035
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APPENDIX B
QUESTIONNAIRE: PRACTICE, KNOWLEDGE AND BARRIERS FOR SCREENING OF
HEPATOCELLULAR CARCINOMA AMONG HIGH-RISK CHINESE PATIENTS

Part I.
Please provide some basic information about yourself
1. Age：

_______

2. Gender：

A. Male

B. Female

3. Current region of residence：

A. Rural

B. Urban

4. Household registration:

A. Rural

B. Urban

5. Education level：
A. Middle school or below

B. High school

C. College or above
6. Annual household income：
A. <40,000 RMB

B. 40,000 - 80,000 RMB

C. 80,000 - 150,000 RMB

D. >150,000 RMB

7. Medical insurance：
A. Urban Employee’s Basic Medical Insurance
B. Urban Resident Basic Medical Insurance
C. New Rural Cooperative Medical System
D. Other: ________________
E. Out-of-pocket
8. Any immediate family member diagnosed with liver cancer?

Yes or No

9. How long have you been diagnosed with hepatitis infection: ________
10. Do you have liver cirrhosis?

Yes or No

11. Do you have any of the following chronic condition(s)?
A. Hypertension

B. Diabetes

D. Stroke

E. Cancer

F. Other chronic condition：_____________

C. Cardiovascular disease

G. None
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Part II.
1. Have you ever received ultrasound of the liver?

Yes or No

2. Have you ever had alpha-fetoprotein (AFP) of the liver?

Yes or No

3. Prior to participate in this study, did you know about the purpose of AFP test?
Yes or No

If answered YES to have received ultrasound or AFP
 Please state when was the last time you had ultrasound: ___________
 Please state about how often do you get ultrasound: ___________
 Please state when was the last time you had AFP: ___________
 Please state about how often do you get AFP: ___________
 Were the screening tests provided by your employer or did you choose to
undergo screening? ____________
 If provided by employer, please state the type of employment
organization: ___________

If answered NO, please choose the reason(s) for not having undergone screening
(more than one choice is allowed):
 Do not know the benefits of screening (

)

 Financially difficult to afford screening (

)

 Not aware that screening for liver cancer exists (

)

 Since liver cancer is difficult to treat, why bother undergo screening (
 No symptoms or discomfort (

)

 Lack of recommendation from physicians (
 Lack of time (

)

)

 Difficulty in accessing medical facilities (

)

 Other (please state the reason): _____________

)
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Part III. For the questions below, please choose the correct answer
1. Is HBV or HCV commonly transmitted through consuming contaminated food?
Yes or No
2. Can HBV or HCV be transmitted through sexual intercourse?
Yes or No
3. Is excessive alcohol consumption considered a risk factor for liver cancer?
Yes or No
4. Have you heard of aflatoxin and its role in liver cancer?
Yes or No
5. Does chronic hepatitis have to cause cirrhosis before developing liver cancer?
Yes or No
6. Can liver cancer metastasize to other organs in the body?
Yes or No
7. Do symptoms usually show up in the early stage of liver cancer?
Yes or No
8. Which of the choices are common symptoms of liver cancer?
A. Yellow of the skin

B. Persistent headaches

C. Shortness of breath

D. Unexplained weight loss

9. Which of the following lifestyles are important to prevent from developing liver
cancer?
A. Smoking cessation

B. Alcohol drinking cessation

C. Limit the intake of salty food

D. Consumption of high fruit and vegetables

E. All the above
10. Which of the two choices are the most common tests used for liver cancer
screening?
A. X-ray

B. AFP

B. Ultrasound

D. CT scan

11. How often should patients with chronic hepatitis undergo liver cancer screening?
A. Whenever symptoms appear

B. At least every half year

C. Once every two years

D. Don’t know

12. When should patients with chronic hepatitis to start undergo liver cancer
screening?
A. Whenever symptoms appear

B. Men at age 35, women at age 45

C. Men at age 45, women at age 55

D. Don’t know
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APPENDIX C
QUESTIONNAIRE: ADHERENCE AND PERCEIVED BARRIERS TO ORAL ANTIVIRAL
THERAPY FOR CHRONIC HEPATITIS B

Part I. Basic Demographic and Clinical Information
1. Age: ______
2. Gender:

A. Male

B. Female

3. Current region of residence:

A. Rural

B. Urban

4. Education level:
A. Middle school or below

B. High school

C. College or above

5. Annual household income (RMB):
A. <50,000

B. 50,000 to 80,000

C. 80,000 to 150,000

D. >150,000

6. Health insurance status:
A. Urban Employee’s Basic Medical Insurance
B. Urban Resident Basic Medical Insurance
C. New Rural Cooperative Medical System
D. Other: ________________
E. Out-of-pocket
7. How long have you been diagnosed with HBV infection? ________
8. Do you have liver cirrhosis?

Yes or No

Part II. The 8-item Morisky Medication Adherence Scale (MMAS-8).
Patient
answer
(Yes or No)
1. Do you sometimes forget to take your antiviral medication(s)?
2. People sometimes miss taking their medication(s) for reasons
other than forgetting. Thinking over the past two weeks, were
there any days when you did not take your antiviral medication(s)?
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3. Have you ever cut back or stopped taking your antiviral
medication(s) without telling your doctor because you felt worse
when you took it?
4. When you travel or leave home, do you sometimes forget to
bring along your antiviral medication(s)?
5. Did you take all your antiviral medication(s) yesterday?
6. When you feel like your symptoms are under control, do you
sometimes stop taking your antiviral medication(s)?
7. Taking antiviral medication(s) every day is a real inconvenience
for some people. Do you ever feel hassled about sticking to your
treatment plan?
8. How often do you have difficulty remembering to take all your
antiviral medication(s)?
A. Never/Rarely
B. Once in a while
C. Sometimes
D. Usually
E. All the time
Use of the ©MMAS is protected by US and International copyright laws. © 2006
Donald E. Morisky Permission for use is required. A license agreement is available
from: Donald E. Morisky, MMAS Research (MORISKY), 294 Lindura Court, Las Vegas,
NV 89135-1415; dmorisky@gmail.com.

Part III. Potential Barriers to Antiviral Medication Adherence
If you did not obtain a score of 8 on MMAS scale, please check the reason (s) that apply:


Forgetfulness (



Cannot tell the difference between taking and not taking medication(s) (



Feel better already and do not think it is necessary to continue (



Have experienced side effects or worry about potential side effects (



Physician did not inform me about importance of taking medication(s) regularly
(

)

)
)

)
)
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Ran out of pills and have no time to refill (



Multiple medications are taken daily and cannot remember the dose (



All medication(s) are paid out-of-pocket; it is difficult to afford them (



Insurance does not provide coverage when cost exceeds the limit (



Do not want others to know that I am taking medication(s) (



Other reason (please specify): ___________

)
)
)
)

)

Part IV. Treatment-related Characteristics and Perception of Disease
1. Which HBV antiviral medication(s) are you taking? _________
2. How long have you been taking the antiviral medication(s)? _________
3. Other than antiviral medication(s), are you also taking other medication (e.g.
traditional Chinese Medicine) or utilizing other treatments for HBV?
A. If yes, please specify: _________

B. No

4. Do you have other chronic diseases? If so, how many? _________ To treat
these illnesses, how many pills are you taking per day? (does not include HBV
medication(s)) __________
5. Do you understand everything the physician says during your consultation about
HBV medication(s)?
A. Yes

B. No

6. Are you using any memory aids (e.g. phone alarm, clock alarm) for antiviral
treatment?
A. Yes

B. No

7. Do your family members remind you to take antiviral treatment on time?
A. Yes

B. No

8. Do you think that antiviral treatment is effective?
A. Yes

B. No

C. I don’t know

9. How would you rate your current HBV condition?
A. Severe

B. Moderate

C. Mild

D. Don’t know

10. How would you rate your overall health condition?
A. Very good

B. Good

C. Fair

D. Poor

